ATE275198T1 - Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. - Google Patents

Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.

Info

Publication number
ATE275198T1
ATE275198T1 AT92924775T AT92924775T ATE275198T1 AT E275198 T1 ATE275198 T1 AT E275198T1 AT 92924775 T AT92924775 T AT 92924775T AT 92924775 T AT92924775 T AT 92924775T AT E275198 T1 ATE275198 T1 AT E275198T1
Authority
AT
Austria
Prior art keywords
antibodies
mammal
rgdp
species
self
Prior art date
Application number
AT92924775T
Other languages
English (en)
Inventor
Andrew David Lilac C Griffiths
Hendricus Renerus J Hoogenboom
James David Marks
John Mccafferty
Gregory Paul Winter
Geoffrey Walter Grigg
Original Assignee
Medical Res Council
Cambridge Antibody Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE275198(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919125582A external-priority patent/GB9125582D0/en
Priority claimed from GB919125579A external-priority patent/GB9125579D0/en
Priority claimed from GB929206318A external-priority patent/GB9206318D0/en
Priority claimed from GB929206372A external-priority patent/GB9206372D0/en
Priority claimed from PCT/GB1992/001755 external-priority patent/WO1993006213A1/en
Application filed by Medical Res Council, Cambridge Antibody Tech filed Critical Medical Res Council
Application granted granted Critical
Publication of ATE275198T1 publication Critical patent/ATE275198T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
AT92924775T 1991-12-02 1992-12-02 Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. ATE275198T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB919125582A GB9125582D0 (en) 1991-12-02 1991-12-02 Binding molecules 2
GB919125579A GB9125579D0 (en) 1991-07-10 1991-12-02 Binding molecules 1
GB929206318A GB9206318D0 (en) 1992-03-24 1992-03-24 Binding substances
GB929206372A GB9206372D0 (en) 1992-03-24 1992-03-24 Binding substances
PCT/GB1992/001755 WO1993006213A1 (en) 1991-09-23 1992-09-23 Production of chimeric antibodies - a combinatorial approach
PCT/GB1992/002240 WO1993011236A1 (en) 1991-12-02 1992-12-02 Production of anti-self antibodies from antibody segment repertoires and displayed on phage

Publications (1)

Publication Number Publication Date
ATE275198T1 true ATE275198T1 (de) 2004-09-15

Family

ID=27450782

Family Applications (3)

Application Number Title Priority Date Filing Date
AT00107845T ATE408012T1 (de) 1991-12-02 1992-12-02 Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
AT92924775T ATE275198T1 (de) 1991-12-02 1992-12-02 Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
AT06001908T ATE463573T1 (de) 1991-12-02 1992-12-02 Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00107845T ATE408012T1 (de) 1991-12-02 1992-12-02 Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06001908T ATE463573T1 (de) 1991-12-02 1992-12-02 Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken

Country Status (7)

Country Link
US (10) US5885793A (de)
AT (3) ATE408012T1 (de)
DE (2) DE69233745D1 (de)
DK (1) DK1024191T3 (de)
ES (3) ES2313867T3 (de)
PT (2) PT1024191E (de)
WO (1) WO1993011236A1 (de)

Families Citing this family (1628)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) * 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
GB9206318D0 (en) * 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
JP3507073B2 (ja) * 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
CA2150262C (en) * 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
GB9225453D0 (en) * 1992-12-04 1993-01-27 Medical Res Council Binding proteins
AU690171B2 (en) * 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
EP1231268B1 (de) 1994-01-31 2005-07-27 Trustees Of Boston University Bibliotheken aus Polyklonalen Antikörpern
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
ES2176484T3 (es) * 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
GB9621295D0 (en) * 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
AU1127097A (en) * 1995-12-15 1997-07-14 Pharmacia & Upjohn Company Method for the simultaneous detection of a therapeutic target for a disease state and its neutralizing antibody-like molecule
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
ATE200679T1 (de) * 1997-04-14 2001-05-15 Micromet Ag Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU9395398A (en) * 1997-09-19 1999-04-12 Chiron Corporation Subtractive protein screening for gene identification
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
EP1060395B1 (de) 1998-02-04 2008-04-30 Invitrogen Corporation Microarrays und ihre verwendungen
US6479256B1 (en) 1998-03-04 2002-11-12 Icos Corporation Lectomedin materials and methods
EP1093457B8 (de) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
CA2329908A1 (en) * 1998-04-24 1999-11-04 The Regents Of The University Of California Targeted gene delivery to cells by filamentous bacteriophage
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
EP1078051B1 (de) 1998-05-13 2007-12-12 Domantis Limited Phagen-display-selektionssystem für korrekt gefaltete proteine
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
DE69941453D1 (de) 1998-06-12 2009-11-05 Genentech Inc Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
US20020119579A1 (en) * 1998-07-14 2002-08-29 Peter Wagner Arrays devices and methods of use thereof
US6780582B1 (en) * 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6576478B1 (en) * 1998-07-14 2003-06-10 Zyomyx, Inc. Microdevices for high-throughput screening of biomolecules
US20030138973A1 (en) * 1998-07-14 2003-07-24 Peter Wagner Microdevices for screening biomolecules
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
MXPA01007163A (es) 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
AU2750800A (en) 1999-02-01 2000-08-18 Amgen Canada Inc. Materials and methods to inhibit hodgkin and reed sternberg cell growth
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
AU3501700A (en) 1999-02-26 2000-09-14 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6890726B1 (en) 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
KR20020000223A (ko) * 1999-05-14 2002-01-05 존 비. 랜디스 표피성장인자 수용체 길항제를 사용한 인간 난치성 종양의치료 방법
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
CN1370076A (zh) 1999-08-23 2002-09-18 中外制药株式会社 Hm1.24抗原的表达增强剂
US7084256B2 (en) * 1999-09-24 2006-08-01 Large Scale Biology Corporation Self antigen vaccines for treating B cell lymphomas and other cancers
US20030039659A1 (en) * 1999-09-24 2003-02-27 Mccormick Alison A. Self antigen vaccines for treating B cell lymphomas and other cancers
EP1224327A4 (de) 1999-09-29 2004-09-08 Xenoport Inc Zusammensetzungen auf genetisch replizierbaren produkten und methoden zu deren verwendung
US7037706B1 (en) 1999-09-29 2006-05-02 Xenoport, Inc. Compounds displayed on replicable genetic packages and methods of using same
US6344549B1 (en) 1999-10-14 2002-02-05 Icos Corporation ATR-2 cell cycle checkpoint
WO2001031005A2 (en) 1999-10-22 2001-05-03 Pharmacia & Upjohn Company Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US6498026B2 (en) 2000-02-25 2002-12-24 Hercules Incorporated Variant galactose oxidase, nucleic acid encoding same, and methods of using same
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
ES2531551T3 (es) * 2000-04-17 2015-03-17 Dyax Corp. Métodos para construir bibliotecas de presentación de paquetes genéticos para miembros de una familia diversa de péptido
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
EP1283909A4 (de) * 2000-05-04 2006-06-07 Univ Yale Proteinarrays mit hoher dichte zum screenen von proteinaktivität
US6734005B2 (en) 2000-05-22 2004-05-11 Pharmacia & Upjohn Company Matrix metalloproteinases
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
EP2431054A3 (de) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Menschlicher Tumornekrosefaktor Delta und Ypsilon
ES2609016T3 (es) 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
HUP0301002A3 (en) * 2000-06-29 2005-12-28 Abbott Lab Dual specificity antibodies and methods of making and using
WO2002002639A2 (en) 2000-07-05 2002-01-10 Pharmacia & Upjohn Company Human ion channels
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
EP1311291A4 (de) * 2000-08-09 2007-07-25 Imclone Systems Inc Behandlung von hyperproliferativen krankheiten mit antagonisten des epidermalen wachstumsfaktors
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
GB0025144D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
ATE352040T1 (de) * 2000-11-17 2007-02-15 Univ Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
EP2338512A1 (de) 2000-11-28 2011-06-29 MedImmune, LLC Verfahren zur Verabreichung/Dosierung von Anti-RSV-Antikörpern zur Prophylaxe und Behandlung
EP1355919B1 (de) 2000-12-12 2010-11-24 MedImmune, LLC Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20030119056A1 (en) 2000-12-18 2003-06-26 Ladner Robert Charles Focused libraries of genetic packages
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2002086096A2 (en) * 2001-01-23 2002-10-31 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
AU2002251913A1 (en) * 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
WO2002064159A1 (en) 2001-02-07 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Remedies for tumor in hematopoietic organs
CN1564826A (zh) 2001-02-09 2005-01-12 人类基因组科学公司 人类g蛋白趋化因子受体(ccr5)hdgnr10
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) * 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
WO2002077182A2 (en) 2001-03-21 2002-10-03 Xenoport, Inc. Compounds displayed on icosahedral phage and methods of using same
EP1383802A4 (de) * 2001-03-30 2005-08-03 Univ California Anti-muc-1-einzelkettenantikörper zum targeting von tumoren
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
WO2002092771A2 (en) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
KR100942393B1 (ko) 2001-05-25 2010-02-17 휴먼 게놈 사이언시즈, 인코포레이티드 Ｔｒａｉｌ 수용체에 면역특이적으로 결합하는 항체
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
AU2002303929B9 (en) * 2001-05-31 2007-01-25 E. R. Squibb & Sons, L.L.C. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003035842A2 (en) * 2001-10-24 2003-05-01 Dyax Corporation Hybridization control of sequence variation
US7175983B2 (en) * 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
SI1461428T1 (sl) 2001-12-03 2012-07-31 Alexion Pharma Inc Postopek za proizvodnjo hibridnih protiteles
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20050095712A1 (en) * 2002-01-17 2005-05-05 Alberto Martin Mutations caused by activation-induced cytidine deaminase
JP2005523688A (ja) * 2002-01-18 2005-08-11 ブリストル−マイヤーズ　スクイブ　カンパニー タンパク質チロシンキナーゼおよび／またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
US20050118163A1 (en) 2002-02-14 2005-06-02 Hidefumi Mizushima Antibody-containing solution pharmaceuticals
MY157727A (en) 2002-02-25 2016-07-15 Biogen Idec Inc Administration of agents for the treatment of inflamation
JP2005526506A (ja) 2002-03-04 2005-09-08 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的なヒト抗体及びその利用
US20030216551A1 (en) * 2002-03-08 2003-11-20 Diabetogen Biosciences Inc. Fully human anti-CD3 monoclonal antibodies
US20030186221A1 (en) * 2002-04-02 2003-10-02 Lockhart David J. Phage display affinity filter and forward screen
US7112435B1 (en) 2002-08-07 2006-09-26 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
SI1997512T1 (sl) 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Postopki za zdravljenje stanj, povezanih s TWEAK-om
CA2481747A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
EP1513879B1 (de) 2002-06-03 2018-08-22 Genentech, Inc. Bibliotheken synthetischer antikörperphagen
AU2003274463B2 (en) 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
JP2006512895A (ja) * 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
JP4660189B2 (ja) * 2002-07-03 2011-03-30 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 抗血小板自己抗体およびそのインヒビターに関連する組成物、方法およびキット
PT2269656E (pt) 2002-07-15 2014-12-02 Univ Texas Anticorpos selecionados e peptídeos de duramicina que se ligam a fosfolipídios aniônicos e aminofosfolipídios e seus usos no tratamento de infecções virais e câncer
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
WO2004013290A2 (en) * 2002-08-05 2004-02-12 Invitrogen Corporation Compositions and methods for molecular biology
US7897381B2 (en) * 2002-08-07 2011-03-01 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
US7833741B2 (en) * 2002-08-07 2010-11-16 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
EP1534335B9 (de) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
US20050233473A1 (en) * 2002-08-16 2005-10-20 Zyomyx, Inc. Methods and reagents for surface functionalization
EP1541165A4 (de) 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd Verfahren zur stabilisierung einer proteinl sungszubereitung
EP2261230B1 (de) 2002-09-11 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Verfahren zur Proteinreinigung
CN101812134A (zh) 2002-10-16 2010-08-25 欧洲凯尔特公司 结合细胞缔合的ca125/o772p的抗体及其使用方法
GB2395270B (en) * 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
US6974860B2 (en) * 2002-12-30 2005-12-13 Kimberly-Clark Worldwide, Inc. Target recognizing binding agents
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7259002B2 (en) * 2003-01-21 2007-08-21 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
CA2514117A1 (en) 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20040248798A1 (en) 2003-02-14 2004-12-09 Peter Sutovsky Contraceptive methods and compositions related to proteasomal interference
CA2516455C (en) 2003-02-20 2012-05-01 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
SI2248899T1 (sl) 2003-03-19 2015-07-31 Biogen Ma Inc. Vezavni protein receptorja Nogo
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP1622942B1 (de) 2003-05-01 2014-11-19 ImClone LLC Komplett menschliche antikörper gegen den rezeptor des insulin-ähnlichen wachstumsfaktor i
EP2357237A1 (de) 2003-05-14 2011-08-17 Domantis Limited Verfahren zur gewinnung aus einem polypeptid - repertoire von polypeptiden, die sich reversibel entfalten
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CA2525130C (en) 2003-05-20 2014-04-15 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US8784821B1 (en) 2003-05-31 2014-07-22 Amgen Research (Munich) Gmbh Human-anti-human cd3 binding molecules
US20040248323A1 (en) * 2003-06-09 2004-12-09 Protometrix, Inc. Methods for conducting assays for enzyme activity on protein microarrays
WO2005017155A1 (ja) 2003-06-18 2005-02-24 Chugai Seiyaku Kabushiki Kaisha フコーストランスポーター
EP1644513B1 (de) 2003-06-20 2011-08-10 DiscoveRx Corporation Test zum nachweis von proteinbindung
AU2004259727A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases.
PT1648998E (pt) 2003-07-18 2014-11-04 Amgen Inc Agentes de ligação específica ao factor de crescimento do hepatócito
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
ATE528397T1 (de) 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
JP2007511738A (ja) 2003-08-08 2007-05-10 ジーンニュース インコーポレーテッド 変形性関節症のバイオマーカー及びその使用
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
US20120202710A1 (en) * 2003-09-09 2012-08-09 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
US7046714B2 (en) * 2003-09-10 2006-05-16 Intel Corporation Method and apparatus for Raman ring resonator based laser/wavelength converter
CA2538763C (en) * 2003-09-11 2015-05-05 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
US7662929B2 (en) 2003-10-10 2010-02-16 Alchemia Oncology Pty Limited Antibody that specifically binds hyaluronan synthase
DE602004013825D1 (de) 2003-11-21 2008-06-26 Ucb Pharma Sa Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
NZ547591A (en) * 2003-12-04 2009-11-27 Vaccinex Inc Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
ES2537163T3 (es) 2003-12-10 2015-06-03 E. R. Squibb & Sons, L.L.C. Anticuerpos de IP-10 y sus usos
KR101225299B1 (ko) 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
PT2805728T (pt) 2003-12-23 2020-04-08 Genentech Inc Novos anticorpos anti-il13 e o uso dos mesmos
EP1761561B1 (de) 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antikörper-spezifitätstransfer mit minimal essentiell bindenden determinanten
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
ATE452147T1 (de) 2004-02-19 2010-01-15 Genentech Inc Antikörper mit korrigierten cdr
WO2005087177A2 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
AU2005224267B2 (en) 2004-03-19 2011-07-21 Imclone Llc Human anti-epidermal growth factor receptor antibody
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
ES2482142T3 (es) 2004-04-15 2014-08-01 University Of Florida Research Foundation, Inc. Proteínas neurales como biomarcadores para lesiones del sistema nervioso y otros trastornos neurales
JP2008501638A (ja) 2004-04-23 2008-01-24 ドイツ連邦共和国 ＩＣＯＳ陽性細胞のｉｎｖｉｖｏ枯渇によるＴ細胞介在病態の治療方法
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
BRPI0510909A2 (pt) * 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
US9228008B2 (en) 2004-05-28 2016-01-05 Idexx Laboratories, Inc. Canine anti-CD20 antibodies
BRPI0511755A (pt) 2004-06-01 2008-01-02 Domantis Ltd composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
EP1753783B1 (de) * 2004-06-03 2014-08-06 Novimmune SA Anti-cd3-antikörper und verfahren zu deren anwendung
KR101541658B1 (ko) 2004-06-21 2015-08-07 메다렉스, 엘.엘.시. 인터페론 알파 수용체 1 항체 및 그의 용도
EP2474317A1 (de) 2004-06-24 2012-07-11 Biogen Idec MA Inc. Behandlung von Zuständen einhergehend mit Demyelisation
US8822644B2 (en) 2004-08-02 2014-09-02 Zenyth Operations Pty Ltd Method of treating cancer comprising a VEGF-B antagonist
EP2329714A1 (de) 2004-08-03 2011-06-08 Biogen Idec MA Inc. Einfluss von TAJ in den neuronalen Funktionen
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060148104A1 (en) * 2004-10-29 2006-07-06 Massachusetts Institute Of Technology Detection of ion channel or receptor activity
ES2523457T3 (es) 2004-11-18 2014-11-26 Imclone Llc Anticuerpos contra el receptor 1 del factor de crecimiento endotelial vascular
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
EP1841796A2 (de) 2004-12-02 2007-10-10 Domantis Limited Bispezifische domänen-antikörper gegen serum albumin und glp-1 oder pyy
CA2585104A1 (en) 2004-12-06 2006-06-15 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
US20060134698A1 (en) * 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
PT1835922E (pt) * 2004-12-22 2009-07-08 Merck Serono Sa Tratamento combinado para esclerose múltipla
EP1829961A4 (de) 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd Verfahren zur herstellung eines antikörpers unter verwendung einer zelle mit gehemmter fucosetransporterfunktion
JP5265923B2 (ja) 2005-02-07 2013-08-14 ジーンニュース インコーポレーテッド 軽度の変形性関節症のバイオマーカーおよびその使用
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
WO2006086733A2 (en) * 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
EP1853718B1 (de) 2005-02-15 2015-08-05 Duke University Anti-cd19-antikörper und ihre verwendung in der onkologie
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
PT1851250E (pt) * 2005-02-18 2012-08-27 Medarex Inc Anticorpo monoclonal humano para o antigénio membranar específico da próstata (psma)
EP1858545A2 (de) 2005-03-04 2007-11-28 Curedm Inc. Verfahren und pharmazeutische zusammensetzungen zur behandlung von diabetes mellitus typ 1 und anderer erkrankungen
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
GB0506912D0 (en) 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
US9296816B2 (en) 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
CN101203241B (zh) 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
CA2607281C (en) 2005-05-05 2023-10-03 Duke University Anti-cd19 antibody therapy for autoimmune disease
PL2439273T3 (pl) 2005-05-09 2019-08-30 Ono Pharmaceutical Co., Ltd. Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
AU2006244014B2 (en) 2005-05-10 2011-03-17 Biogen Ma Inc. Treating and evaluating inflammatory disorders
CA2726759C (en) 2005-05-25 2016-02-16 Curedm Group Holdings, Llc Human proislet peptide, derivatives and analogs thereof, and methods of using same
EP2460831B1 (de) * 2005-05-27 2016-10-19 Biogen MA Inc. Tweak-bindende antikörper
SI1889059T1 (sl) 2005-05-27 2009-12-31 Oncimmune Ltd Izboljšani imunotestni postopek
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
KR101502920B1 (ko) 2005-06-21 2015-03-17 조마 (유에스) 엘엘씨 ＩＬ-１β 결합성 항체 및 그의 단편
WO2007094842A2 (en) 2005-12-02 2007-08-23 Genentech, Inc. Binding polypeptides and uses thereof
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
PL1896073T3 (pl) 2005-06-30 2013-08-30 Janssen Biotech Inc Przeciwciała anty-IL-23, kompozycje, sposoby i zastosowania
US7700739B2 (en) 2005-06-30 2010-04-20 Abbott Laboratories IL-12/p40 binding proteins
RS54271B1 (en) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US7482124B2 (en) * 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
ES2539250T3 (es) 2005-07-25 2015-06-29 Emergent Product Development Seattle, Llc Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20
CA2617594C (en) 2005-08-03 2016-08-02 Grains Research & Development Corporation Polysaccharide synthases
SI2573114T1 (sl) 2005-08-10 2016-08-31 Macrogenics, Inc. Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo
CA2619244A1 (en) * 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
EP2500357A3 (de) 2005-08-19 2012-10-24 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
MY169746A (en) 2005-08-19 2019-05-14 Abbvie Inc Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2390826T3 (es) * 2005-08-24 2012-11-16 Immunogen Inc Procedimiento para preparar conjugados de fármaco purificados
US20100209437A1 (en) * 2005-09-12 2010-08-19 Greg Elson Anti-CD3 Antibody Fromulations
AU2006290567A1 (en) 2005-09-14 2007-03-22 Ucb Pharma S.A Comb polymers
BRPI0617546A2 (pt) 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
BRPI0617549A2 (pt) 2005-09-26 2011-07-26 Medarex Inc anticorpo monoclonal humano isolado, anticorpo monoclonal humano isolado ou uma porÇço ligante ao antÍgeno do mesmo, composiÇço, imunoconjugado, molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-cd70, mÉtodo para tratar ou prevenir uma doenÇa, mÉtodo para tratar uma doenÇa autoimune em um indivÍduo, mÉtodo para tratar uma inflamaÇço em um indivÍduo, mÉtodo para tratar uma infecÇço viral em um indivÍduo, anticorpo ou porÇço ligante ao antÍgeno do mesmo e uso de um anticorpo ou de uma porÇço ligante ao antÍgeno do mesmo
WO2007039256A2 (de) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
CN101330930B (zh) 2005-10-21 2011-11-23 中外制药株式会社 心脏病治疗剂
EP2532679B1 (de) 2005-10-21 2017-04-12 Novartis AG Menschliche Antikörper gegen IL13 und therapeutische Verwendungen
EP2319941A3 (de) 2005-10-21 2011-08-17 GeneNews Inc. Methode und vorrichtung zur korrelation von biomarker produktmengen mit krankheiten
EP1940789B1 (de) 2005-10-26 2011-11-23 Medarex, Inc. Verfahren und verbindungen zur herstellung von cc-1065-analoga
US20070099246A1 (en) * 2005-11-03 2007-05-03 Sandy John D Antibodies, assays and kits to quantitate cartilage destruction
MY151064A (en) 2005-11-04 2014-03-31 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US20090246189A1 (en) 2005-11-04 2009-10-01 Biogen Idec Ma Inc. And Mclean Hospital Methods for Promoting Neurite Outgrowth and Survival of Dopaminergic Neurons
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
ZA200804082B (en) 2005-11-07 2010-02-24 Scripps Research Inst Compositions and methods for controlling tissue factor signaling specificity
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
JP5398987B2 (ja) 2005-11-14 2014-01-29 セルミド リミテッド 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US20090269335A1 (en) 2005-11-25 2009-10-29 Keio University Therapeutic agent for prostate cancer
EP2805971A1 (de) 2005-11-28 2014-11-26 ZymoGenetics, Inc. IL-21-Antagonisten
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
US8497072B2 (en) * 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
JP5312039B2 (ja) 2005-12-02 2013-10-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄の関与する状態の処置
CN101356195B (zh) 2005-12-08 2013-04-03 米德列斯公司 抗岩藻糖基-gm1的人单克隆抗体及使用抗岩藻糖基-gm1抗体的方法
PL1960430T3 (pl) 2005-12-09 2015-03-31 Ucb Pharma Sa Cząsteczki przeciwciał wykazujące swoistość dla ludzkiej il-6
EP1803814A1 (de) 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Methode zur Verbesserung der Antikörperselektionskapazität in einer Phagen-Display-Bibliothek
EP1977763A4 (de) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Antikörper-enthaltende stabilisierende zubereitung
RS53685B1 (en) 2005-12-29 2015-04-30 Janssen Biotech Inc. HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS
US20070160325A1 (en) * 2006-01-11 2007-07-12 Hyungbin Son Angle-tunable transmissive grating
US20070166774A1 (en) * 2006-01-17 2007-07-19 Groman Ernest V Functional immunoassay
CN104189907A (zh) 2006-01-27 2014-12-10 学校法人庆应义塾 伴有脉络膜血管生成的疾病的治疗药
CN103215293B (zh) 2006-01-27 2015-10-28 比奥根Ma公司 Nogo受体拮抗剂
WO2007090126A2 (en) * 2006-01-30 2007-08-09 Invitrogen Corporation Compositions and methods for detecting and quantifying toxic substances in disease states
NZ569988A (en) * 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
EP1999148B8 (de) 2006-03-06 2014-03-05 Medlmmune, LLC Humanisierte anti-cd22-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
EP2009101B1 (de) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antikörpermodifikationsverfahren für die aufreinigung eines bispezifischen antikörpers
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US7910798B2 (en) 2006-03-31 2011-03-22 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
US20100080794A1 (en) 2006-04-14 2010-04-01 Takashi Tsuji Mutant polypeptide having effector function
EP1918302A3 (de) * 2006-05-18 2009-11-18 AvantGen, Inc. Verfahren zur Identifikation und Isolation von epitopspezifischen Antikörpern
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
JP5043008B2 (ja) 2006-06-08 2012-10-10 中外製薬株式会社 炎症性疾患の予防または治療剤
CA2654317A1 (en) * 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
EP2037961B1 (de) 2006-06-14 2015-11-11 MacroGenics, Inc. Verfahren zur behandlung von autoimmunerkrankungen anhand von monoklonalen antikörpern mit verminderter toxizität
US8874380B2 (en) 2010-12-09 2014-10-28 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
WO2008019199A2 (en) 2006-06-26 2008-02-14 Macrogenics, Inc. FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
KR20090038896A (ko) 2006-07-13 2009-04-21 추가이 세이야쿠 가부시키가이샤 세포사 유도제
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
WO2008010556A1 (fr) 2006-07-21 2008-01-24 Chugai Seiyaku Kabushiki Kaisha Médicament agissant contre une maladie rénale
ES2396220T3 (es) 2006-08-11 2013-02-20 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales frente al factor 1 derivado del estroma (SDF-1)
JP5235881B2 (ja) * 2006-08-11 2013-07-10 シーエスエル、リミテッド 肺疾患病態の処理
EP3111955B1 (de) 2006-08-14 2019-01-23 Chugai Seiyaku Kabushiki Kaisha Diagnose und behandlung von krebs mittels anti-desmoglein-3 antikörper
TW201441262A (zh) 2006-08-18 2014-11-01 Novartis Ag 催乳激素受體（ｐｒｌｒ）之專一性抗體及其用途
DK2484696T3 (en) 2006-08-28 2017-10-02 Kyowa Hakko Kirin Co Ltd Antagonistic hLIGHT-specific human monoclonal antibodies
EA200970250A1 (ru) 2006-09-05 2010-02-26 Медарекс, Инк. Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
ES2817756T3 (es) 2006-09-08 2021-04-08 Abbvie Bahamas Ltd Proteínas de unión a interleuquina-13
US8574848B2 (en) 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
US20090252745A1 (en) * 2006-09-15 2009-10-08 Duke University Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis
WO2008036973A2 (en) 2006-09-22 2008-03-27 St. Jude Children's Research Hospital Modulating regulatory t cell activity via interleukin 35
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
BRPI0718197A2 (pt) 2006-10-02 2014-09-30 Medarex Inc Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, e, métodos para preparar um anticorpo anti-cxcr4, para modular a atividade do cxcr4 em uma célula, e para estimular a mobilização de células tronco cd34+ da medula óssea para o sangue periférico em um indivíduo.
CN101594883B (zh) 2006-10-12 2018-04-10 中外制药株式会社 使用抗ereg抗体的癌症的诊断和治疗
JP2010506842A (ja) 2006-10-16 2010-03-04 メディミューン，エルエルシー 半減期が短縮された分子、その組成物および使用
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
EP1914242A1 (de) 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
EP2530090A3 (de) 2006-10-19 2013-01-23 CSL Limited Anti-IL-13R alpha 1-Antikörper und Verwendung davon
JP5238710B2 (ja) 2006-10-19 2013-07-17 シーエスエル、リミテッド インターロイキン−１３レセプターアルファ１の高親和性抗体アンタゴニスト
CA2666559A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
CA2666809A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Anti-cancer agent comprising anti-hb-egf antibody as active ingredient
MX2009004881A (es) 2006-11-09 2009-05-21 Irm Llc Anticuerpos agonistas de trkb y usos de los mismos.
WO2008076560A2 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use
WO2008064306A2 (en) 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
US20080199475A1 (en) 2006-11-27 2008-08-21 Patrys Limited Novel glycosylated peptide target in neoplastic cells
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
ATE555128T1 (de) 2006-11-30 2012-05-15 Res Dev Foundation Verbesserte immunglobulin-bibliotheken
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN103172743B (zh) 2006-12-01 2015-04-08 梅达雷克斯有限责任公司 结合cd22的人抗体及其用途
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
EP2687232A1 (de) 2006-12-06 2014-01-22 MedImmune, LLC Verfahren zur Behandlung von systemischem Lupus erythematodes
MX2009006034A (es) 2006-12-07 2009-10-12 Novartis Ag Anticuerpos antagonistas contra ephb3.
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
EP2103628A4 (de) 2006-12-14 2012-02-22 Forerunner Pharma Res Co Ltd Monoklonaler anti-claudin-3-antikörper und die behandlung und diagnose von krebs unter dessen verwendung
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
US7935791B2 (en) 2006-12-18 2011-05-03 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
WO2008077145A2 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
US8324350B2 (en) * 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
US20100111851A1 (en) 2007-01-05 2010-05-06 The University Of Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
EP2740744B1 (de) 2007-01-09 2018-03-28 Biogen MA Inc. Sp35-Antikörper und Verwendungen dafür
SG177982A1 (en) 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
AU2008208321B2 (en) 2007-01-23 2013-03-21 Chugai Seiyaku Kabushiki Kaisha Chronic rejection inhibitor
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
ES2431940T3 (es) 2007-02-16 2013-11-28 Merrimack Pharmaceuticals, Inc. Anticuerpos contra la ERBB3 y usos de los mismos
US8114606B2 (en) 2007-02-16 2012-02-14 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
WO2008103475A1 (en) * 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
CL2008000510A1 (es) 2007-02-21 2008-08-22 Medarex Inc Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero.
EP2121745A2 (de) 2007-02-26 2009-11-25 Oxford Genome Sciences (UK) Limited Proteine
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
CA2679266A1 (en) 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
DK2125894T3 (en) 2007-03-22 2019-03-18 Biogen Ma Inc BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, SPECIFICALLY BINDING CD154 AND APPLICATIONS THEREOF
CA2682170A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Antibodies with decreased deamidation profiles
EA018985B1 (ru) 2007-04-02 2013-12-30 Филоджен С.П.А. Новый антиген, ассоциированный с новообразованными сосудами опухолевых метастазов
UA99608C2 (en) 2007-04-17 2012-09-10 Имклоун Ллк PDGFRb-SPECIFIC INHIBITORS
EP2155789B1 (de) 2007-05-01 2013-07-24 Research Development Foundation Immunglobulin-fc-bibliotheken
EP2164868B1 (de) 2007-05-04 2015-03-25 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Gentechnisch gewonnene variable domänen von kaninchen-antikörpern und deren verwendung
EP2737907A3 (de) 2007-05-07 2014-11-05 MedImmune, LLC Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
DK3072525T3 (en) 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
PL2158221T3 (pl) 2007-06-21 2019-02-28 Macrogenics, Inc. Kowalencyjne diaciała i ich zastosowania
AU2009258063B2 (en) 2007-06-21 2014-09-25 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
EP2167130A2 (de) * 2007-07-06 2010-03-31 Trubion Pharmaceuticals, Inc. Bindungspeptide mit einer c-terminal-abgelegten spezifischen bindungsdomäne
WO2009013319A1 (en) * 2007-07-23 2009-01-29 Bioxell Spa Screening, therapy and diagnosis
JP2010534664A (ja) 2007-07-23 2010-11-11 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｉｌ−１７拮抗薬を用いた線維症関連疾患治療の方法及び組成物
CN101754978B (zh) 2007-07-25 2013-06-05 菲洛根股份公司 一种与肺癌和淋巴瘤相关的抗原
EP2174667B1 (de) 2007-07-26 2017-01-04 Osaka University Mittel zur behandlung von augenentzündungen mit interleukin-6-rezeptorhemmer als wirkstoff
ES2453592T3 (es) 2007-08-02 2014-04-08 Novimmune Sa Anticuerpos anti-RANTES y métodos de uso de los mismos
EP2615113A3 (de) 2007-08-23 2013-11-13 Amgen Inc. Antigenbindende Proteine an Proprotein-Konvertase-Subtilisin/Kexin vom Typ 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US8647622B2 (en) 2007-08-29 2014-02-11 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
JP2010538017A (ja) 2007-08-30 2010-12-09 キュアーディーエム、インク． 膵島形成促進性ペプチドおよびそのアナログを使用する組成物および方法
PT2199390T (pt) 2007-08-30 2017-03-15 Daiichi Sankyo Co Ltd Anticorpo anti-epha2
PL2769729T3 (pl) 2007-09-04 2019-09-30 Compugen Ltd. Polipeptydy i polinukleotydy i ich zastosowanie jako cel dla leków do wytwarzania leków i środków biologicznych
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
EP4339294A2 (de) 2007-09-26 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers durch aminosäuresubstitution in cdr
MX2010003158A (es) 2007-09-28 2010-04-14 Chugai Pharmaceutical Co Ltd Anticuerpo anti-glipicano-3 que tiene cinetica mejorada en plasma.
RU2490025C2 (ru) 2007-10-02 2013-08-20 Чугаи Сейяку Кабусики Кайся Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6
HUE025262T2 (en) 2007-10-11 2016-02-29 Daiichi Sankyo Co Ltd Antibody targeting osteoclast-linked Siglec-15 protein
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
KR101558009B1 (ko) 2007-10-15 2015-10-19 추가이 세이야쿠 가부시키가이샤 항체의 제조 방법
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
EA201000603A1 (ru) 2007-10-23 2010-12-30 Новартис Аг ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
EP2230300A4 (de) 2007-10-24 2012-08-08 Otsuka Chemical Holdings Co Ltd Polypeptid mit verbesserter effektorfunktion
EP3783019A1 (de) 2007-10-30 2021-02-24 Philogen S.p.A. Mit rheumatoider arthritis assoziiertes antigen
US20100254980A1 (en) 2007-11-02 2010-10-07 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
RU2530561C2 (ru) 2007-11-05 2014-10-10 Медиммун, Ллк Способы лечения склеродермии
US8236318B2 (en) 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
WO2009063970A1 (ja) 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. 抗gpr49抗体を用いる癌の診断および治療
TW200936160A (en) 2007-11-15 2009-09-01 Chugai Pharmaceutical Co Ltd Monoclonal antibodies that bind to anexelekto and uses thereof
EA201000809A1 (ru) 2007-11-16 2010-12-30 Те Рокфеллер Юниверсити АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА
EP2728017B1 (de) 2007-11-19 2016-08-24 Celera Corporation Lungenkrebsmarker und Verwendungen davon
AR069393A1 (es) 2007-11-21 2010-01-20 Imclone Systems Inc Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
CN101952313B (zh) 2007-11-27 2017-12-15 不列颠哥伦比亚大学 14‑3‑3η抗体及其用于诊断和治疗关节炎的用途
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
GB2468232B (en) 2007-11-30 2012-10-24 Glaxo Group Ltd Antigen-bindng constructs
JP5475460B2 (ja) 2007-12-05 2014-04-16 中外製薬株式会社 掻痒症治療剤
AU2008332271C1 (en) 2007-12-05 2014-04-24 Chugai Seiyaku Kabushiki Kaisha Anti-NR10 antibody and use thereof
US20110262425A1 (en) 2007-12-12 2011-10-27 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
EP2222706B2 (de) 2007-12-14 2016-08-10 Novo Nordisk A/S Antikörper gegen menschliches nkg2d und gebrauch davon
SI2594590T1 (sl) 2007-12-14 2015-03-31 Bristol-Myers Squibb Company Postopek za izdelavo vezavnih molekul za humani receptor OX40
AU2008343085B2 (en) * 2007-12-20 2015-03-12 Xoma (Us) Llc Methods for the treatment of gout
MX2010006735A (es) 2007-12-21 2010-09-30 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
KR101642846B1 (ko) 2007-12-26 2016-07-26 백시넥스 인코포레이티드 항-ｃ35 항체 병용 치료 및 방법
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
JP2011509650A (ja) 2008-01-11 2011-03-31 株式会社ジーンテクノサイエンス ヒト化抗−α９インテグリン抗体及びその使用
CA2711557A1 (en) 2008-01-11 2009-07-16 The University Of Tokyo Anti-cldn6 antibody
JP2011509675A (ja) 2008-01-18 2011-03-31 メディミューン，エルエルシー 部位特異的コンジュゲーションのためのシステイン操作抗体
ES2500066T3 (es) 2008-01-25 2014-09-30 Amgen, Inc Anticuerpos frente a ferroportina y métodos de uso
JP5889533B2 (ja) 2008-01-31 2016-03-22 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変された抗体定常ドメイン分子
KR20100115360A (ko) 2008-02-05 2010-10-27 브리스톨-마이어스 스큅 컴퍼니 알파 ５-베타 １ 항체 및 이의 용도
SG188129A1 (en) 2008-02-08 2013-03-28 Medimmune Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
TWI384997B (zh) 2008-03-12 2013-02-11 Imclone Llc 抗酪胺酸酶相關蛋白-１（ｔｙｒｐ１）抗體
US9873957B2 (en) * 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
BR122012027456A2 (pt) 2008-03-14 2015-07-14 Allergan Inc Composição farmacêutica compreendendo sorotipo de neurotoxina botulínica a
AU2009225797A1 (en) 2008-03-18 2009-09-24 Abbvie Inc. Methods for treating psoriasis
WO2009118300A1 (en) 2008-03-25 2009-10-01 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
AU2009231733B2 (en) 2008-03-31 2015-12-24 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
PT2247304T (pt) 2008-04-02 2016-08-29 Macrogenics Inc Anticorpos especificos de her2/neu e métodos de utilização dos mesmos
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
CN105198997B (zh) * 2008-04-11 2018-08-31 阿普拜佛研发有限责任公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2276509B1 (de) 2008-04-11 2016-06-15 Seattle Genetics, Inc. Nachweis und behandlung von bauchspeicheldrüsen-, eierstock- und anderen karzinomen
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
EP2281078B1 (de) 2008-04-24 2014-10-22 Dyax Corporation Bibliotheken von genetischen packungen, umfassend neue hc-cdr1, -cdr2, und -cdr3, und neue lc-cdr1-, -cdr2- und -cdr3-designs
CN104530233B (zh) 2008-04-24 2018-01-30 株式会社遗传科技 细胞外基质蛋白的氨基酸序列rgd的特异性人源化抗体及其应用
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AU2009243010B2 (en) 2008-04-30 2015-02-05 Immunogen, Inc. Cross-linkers and their uses
AU2009246946B2 (en) 2008-05-01 2013-09-26 Amgen Inc. Anti-hepcidin antibodies and methods of use
ES2458541T3 (es) 2008-05-02 2014-05-06 Seattle Genetics, Inc. Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
MY159667A (en) 2008-05-09 2017-01-13 Abbvie Inc Antibodies to receptor of advanced glycation end products (rage) and uses thereof
EP2599793A1 (de) 2008-05-29 2013-06-05 Nuclea Biotechnologies, Inc. Anti-Phosphor-AKT-Antikörper
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
US9226934B2 (en) 2008-06-02 2016-01-05 The University Of Tokyo Anti-cancer drug
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20110081347A1 (en) 2008-06-04 2011-04-07 Macrogenics, Inc. Antibodies with Altered Binding to FcRn and Methods of Using Same
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
PT2293816E (pt) * 2008-06-06 2013-02-13 Xoma Technology Ltd Métodos para o tratamento da artrite reumatoide
CA2728347A1 (en) 2008-06-16 2010-01-14 Patrys Limited Lm-1 antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
CN102124030B (zh) 2008-06-20 2015-06-17 国立大学法人冈山大学 抗氧化LDL/β2GPI复合物的抗体及其用途
PL2307459T3 (pl) 2008-07-08 2015-05-29 Oncomed Pharm Inc Czynniki wiążące receptor Notch1 i sposoby ich stosowania
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
CA2728909A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 binding proteins and uses thereof
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
WO2010010469A2 (en) * 2008-07-25 2010-01-28 Abbott Gmbh & Co. Kg Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
JP5924937B2 (ja) 2008-07-25 2016-05-25 エックス−ボディ インコーポレイテッド タンパク質スクリーニング法
JP5815403B2 (ja) 2008-08-05 2015-11-17 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MY153074A (en) 2008-08-14 2014-12-31 Teva Pharmaceuticals Australia Pty Ltd Anti-il-12/11-23 antibodies
US8545846B2 (en) 2008-09-05 2013-10-01 Xoma Technology, Ltd. Methods for treating IL-1β related diseases by administering an anti-IL-1β antibody
CA2735433C (en) 2008-09-07 2016-02-16 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
US20120251502A1 (en) 2008-10-24 2012-10-04 The Government of the US as Represented by the Secretary of the Dept. of health Human Ebola Virus Species and Compositions and Methods Thereof
EA028304B1 (ru) 2008-10-31 2017-11-30 Сентокор Орто Байотек Инк. Способы конструирования библиотеки белкового каркаса на основе домена фибронектина типа iii (fn3)
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2010052288A1 (en) 2008-11-07 2010-05-14 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
EP2356146A1 (de) 2008-11-07 2011-08-17 Fabrus Llc Anti-dll4-antikörper und anwendungen davon
CA2743469C (en) 2008-11-12 2019-01-15 Medimmune, Llc Antibody formulation
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
MX2011005874A (es) 2008-12-05 2011-06-27 Glaxo Group Ltd Metodos para seleccionar polipeptidos resistentes a proteasa.
US20110311450A1 (en) 2008-12-08 2011-12-22 Zurit Levine Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
JP5985826B2 (ja) 2008-12-16 2016-09-06 ノバルティス アーゲー 酵母ディスプレイ系
BRPI0918122A8 (pt) 2008-12-19 2017-01-24 Macrogenics Inc molécula de diabody, diabody, e mólecula dart
CA2748990A1 (en) 2008-12-26 2010-07-01 The University Of Tokyo Diagnosis and treatment of cancer using anti-lgr7 antibody
JP2012514458A (ja) 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗リンホトキシン抗体
WO2010078950A2 (en) 2009-01-07 2010-07-15 Philogen S.P.A. Antigens associated with endometriosis, psoriatic arthritis and psoriasis
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
CA2749572A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
WO2010085510A1 (en) 2009-01-20 2010-07-29 Zadeh Homayoun H Antibody mediated osseous regeneration
JP2012515544A (ja) 2009-01-21 2012-07-12 オックスフォード ビオトヘラペウトイクス エルティーディー． Ｐｔａ０８９タンパク質
WO2010085590A1 (en) 2009-01-23 2010-07-29 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA3014224C (en) 2009-02-05 2022-05-24 Immunogen, Inc. Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives
US20120165340A1 (en) 2009-02-11 2012-06-28 Ludwing Institute For Cancer Research Ltd. Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
EP2396011B1 (de) 2009-02-12 2016-04-13 Janssen Biotech, Inc. Auf fibronectin-typ-iii-domain basierende gerüstzusammensetzungen, verfahren und anwendung
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
BRPI1008692B8 (pt) 2009-02-17 2021-05-25 Ucb Biopharma Sprl anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
CA2753332A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
WO2010097394A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
NZ611324A (en) 2009-03-05 2015-02-27 Abbvie Inc Il-17 binding proteins
DK2403878T3 (en) 2009-03-05 2017-09-18 Squibb & Sons Llc CADM1-SPECIFIC FULLY HUMAN ANTIBODIES
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
WO2010104208A1 (en) 2009-03-10 2010-09-16 Gene Techno Science Co., Ltd. Generation, expression and characterization of the humanized k33n monoclonal antibody
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
SI3281953T1 (sl) 2009-03-13 2020-03-31 Allergan, Inc. Na imunosti temelječi testi za aktivnosti ponovno ciljane endopeptidaze
WO2010111702A1 (en) 2009-03-27 2010-09-30 The Research Foundation Of State University Of New York Methods for preventing and treating angioedema
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2010112458A1 (en) 2009-03-31 2010-10-07 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
ES2581488T3 (es) 2009-04-08 2016-09-06 Lipum Ab Nuevos métodos para el tratamiento de enfermedades inflamatorias
US8575316B2 (en) 2009-04-09 2013-11-05 Daiichi Sankyo Company, Limited Anti-Siglec-15 antibody
JP5748653B2 (ja) 2009-04-10 2015-07-15 協和発酵キリン株式会社 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
CA2758964A1 (en) 2009-04-16 2010-10-21 Abbott Biotherapeutics Corp. Anti-tnf-.alpha. antibodies and their uses
SG175734A1 (en) 2009-04-20 2011-12-29 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
NO2424895T3 (de) 2009-04-27 2018-02-03
KR101732201B1 (ko) 2009-04-27 2017-05-02 교와 핫꼬 기린 가부시키가이샤 혈액 종양 치료를 목적으로 하는 항ＩＬ－３Ｒα 항체
JP5723270B2 (ja) 2009-05-01 2015-05-27 国立大学法人 東京大学 抗カドヘリン抗体
UY32608A (es) 2009-05-04 2010-12-31 Pangenetics 110 B V Anticuerpos contra el factor de crecimiento nervioso (ngf) con una estabilidad in vivo mejorada
KR101811886B1 (ko) 2009-05-05 2017-12-22 노비뮨 에스 에이 항―ｉｌ―17ｆ 항체 및 이의 사용 방법
EP2270053A1 (de) 2009-05-11 2011-01-05 U3 Pharma GmbH Humanisierte AXL-Antikörper
JP5797642B2 (ja) * 2009-05-20 2015-10-21 ノビミューン エスアー 合成ポリペプチドライブラリーおよび天然で多様化されたポリペプチドバリアントを作製するための方法
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
NZ596603A (en) 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
HUE043645T2 (hu) 2009-06-03 2019-08-28 Immunogen Inc Konjugációs módszerek
AU2010262836B2 (en) 2009-06-17 2015-05-28 Abbvie Biotherapeutics Inc. Anti-VEGF antibodies and their uses
JP5918129B2 (ja) 2009-06-22 2016-05-18 メディミューン，エルエルシー 部位特異的共役のための操作されたＦｃ領域
EP2445925A1 (de) 2009-06-25 2012-05-02 Bristol-Myers Squibb Company Proteinaufreinigung mittels präzipitation von caprylsäure (octansäure)
JP5683581B2 (ja) * 2009-06-30 2015-03-11 リサーチ ディベロップメント ファウンデーション 免疫グロブリンＦｃポリペプチド
AU2010268690B2 (en) 2009-07-03 2011-11-10 Avipep Pty Ltd Immuno-conjugates and methods for producing them
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
WO2011014645A1 (en) 2009-07-30 2011-02-03 Mount Sinai School Of Medicine Of New York University Influenza viruses and uses thereof
US20120183539A1 (en) 2009-07-31 2012-07-19 Shin Maeda Cancer Metastasis Inhibitor
JP5762408B2 (ja) 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
WO2011021381A1 (ja) 2009-08-17 2011-02-24 株式会社未来創薬研究所 抗hb-egf抗体を有効成分として含む医薬組成物
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
AU2010286518C1 (en) 2009-08-29 2015-08-27 Abbvie Inc. Therapeutic DLL4 binding proteins
RU2012112550A (ru) 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
CA2773564A1 (en) * 2009-09-14 2011-03-17 Dyax Corp. Libraries of genetic packages comprising novel hc cdr3 designs
RU2012114854A (ru) 2009-09-14 2013-10-27 Эбботт Лэборетриз Способы лечения псориаза
CN102630167B (zh) 2009-09-15 2015-06-10 Csl有限公司 神经病的治疗
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
EP2480573A1 (de) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krebs durch modulation von mex-3
WO2011038139A1 (en) 2009-09-23 2011-03-31 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
WO2011037983A1 (en) 2009-09-23 2011-03-31 Medarex, Inc. Cation exchange chromatography
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
US9885711B2 (en) 2009-09-25 2018-02-06 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
WO2011040973A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
WO2011040972A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
JP2013506709A (ja) 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
WO2011044368A1 (en) 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
US8580714B2 (en) 2009-10-14 2013-11-12 Janssen Biotech, Inc. Methods of affinity maturing antibodies
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
US8734798B2 (en) 2009-10-27 2014-05-27 Ucb Pharma S.A. Function modifying NAv 1.7 antibodies
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201122101A (en) 2009-10-28 2011-07-01 Facet Biotech Corp Anti-EGFR antibodies and their uses
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
ES2728115T3 (es) 2009-10-30 2019-10-22 Janssen Biotech Inc Antagonistas de IL-17A
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
EP2496600A1 (de) 2009-11-04 2012-09-12 Fabrus LLC Verfahren zur optimierung von antikörpern auf der basis von affinitätsreifung
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
WO2011058087A1 (en) 2009-11-11 2011-05-19 Gentian As Immunoassay for assessing related analytes of different origin
EP3431608A3 (de) 2009-11-17 2019-02-20 E. R. Squibb & Sons, L.L.C. Verfahren zur erhöhten proteinproduktion
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
WO2011063198A2 (en) * 2009-11-20 2011-05-26 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
AU2010329955A1 (en) 2009-12-08 2012-05-24 Abbott Gmbh & Co. Kg Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
EP2510011B2 (de) 2009-12-09 2021-03-31 Institut National de la Santé et de la Recherche Médicale B7h6 -bindende monoklonale antikörper und ihre verwendung
WO2011084496A1 (en) 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
US9315581B2 (en) 2009-12-23 2016-04-19 A Vipep Pty Limited Immuno-conjugates and methods for producing them
US9005579B2 (en) 2010-01-05 2015-04-14 Contrafect Corporation Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
CN102958534B (zh) 2010-01-13 2014-11-05 昂考梅德药品有限公司 Notch1结合剂及其使用方法
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
WO2011092989A1 (ja) 2010-01-29 2011-08-04 東レ株式会社 ポリ乳酸系樹脂シート
WO2011098449A1 (en) 2010-02-10 2011-08-18 Novartis Ag Methods and compounds for muscle growth
US8815211B2 (en) 2010-02-10 2014-08-26 Fujifilm Ri Pharma Co., Ltd. Radioactive metal-labeled anti-cadherin antibody
BR112012020102A2 (pt) 2010-02-10 2016-11-29 Immunogen Inc anticorpos cd20 e usos dos mesmos.
SG10201503736XA (en) 2010-02-12 2015-06-29 Oncomed Pharm Inc Methods for identifying and isolating cells expressing a polypeptide
US10393754B2 (en) 2010-02-17 2019-08-27 Cedars-Sinai Medical Center Methods of diagnosing and treating heart failure
BR112012020839A2 (pt) 2010-02-18 2017-11-21 Sinai School Medicine vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
DK2538976T3 (en) 2010-02-24 2017-02-27 Immunogen Inc IMMUNCONJUGATES AGAINST FOLATRECEPTOR-1 AND APPLICATIONS THEREOF
EP3072904A1 (de) 2010-03-02 2016-09-28 Abbvie Inc. Therapeutische dll4-bindende proteine
EP2543730B1 (de) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
WO2011107586A1 (en) 2010-03-05 2011-09-09 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, Smoc1, tenascin-c and brain cancers
NZ602176A (en) 2010-03-12 2015-01-30 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
UY33280A (es) 2010-03-17 2011-10-31 Abbott Res Bv Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EP2550297B1 (de) 2010-03-25 2019-01-23 UCB Biopharma SPRL Mit disulfid stabilisierte dvd-lg-moleküle
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
AU2011230537C1 (en) 2010-03-26 2018-08-02 Trustees Of Dartmouth College Vista regulatory T cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
KR20130075732A (ko) 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
US9169325B2 (en) 2010-04-13 2015-10-27 Celldex Therapeutics, Inc. Antibodies that bind human CD27 and uses thereof
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
EP2380909A1 (de) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. An Brustkrebs beteiligtes Protein PTK-7
CA2797274C (en) 2010-04-30 2024-01-23 Centocor Ortho Biotech Inc. Stabilized fibronectin domain compositions, methods and uses
WO2011137395A1 (en) 2010-04-30 2011-11-03 Rother Russell P Anti-c5a antibodies and methods for using the antibodies
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
CA2798273A1 (en) 2010-05-04 2011-11-10 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
PE20130207A1 (es) 2010-05-06 2013-02-28 Novartis Ag Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
BR112012028326A2 (pt) 2010-05-06 2017-03-21 Novartis Ag anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
IL208820A0 (en) 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
EP2566520A4 (de) 2010-05-07 2014-02-12 Xoma Us Llc Verfahren zur behandlung il1-vermittelter störungen
PE20130205A1 (es) 2010-05-14 2013-03-24 Abbvie Inc Proteinas de union a il-1
EP2569335B1 (de) 2010-05-14 2018-08-22 Orega Biotech Verfahren zur behandlung und/oder prävention von zellproliferationsstörungen mit il-17-antagonisten
PL2578231T3 (pl) 2010-05-28 2023-01-16 Chugai Seiyaku Kabushiki Kaisha Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
WO2011154485A1 (en) 2010-06-10 2011-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mammalian sterile 20-like kinase 3
WO2011163401A2 (en) 2010-06-22 2011-12-29 Neogenix Oncology, Inc. Colon and pancreas cancer specific antigens and antibodies
CN103068400A (zh) 2010-06-25 2013-04-24 阿斯顿大学 具有脂类动员性质的糖蛋白及其治疗用途
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
CN106188284B (zh) 2010-07-09 2020-05-08 扬森疫苗与预防公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
KR101963709B1 (ko) 2010-07-16 2019-04-01 아디맵 엘엘씨 항체 라이브러리
NZ604415A (en) 2010-07-20 2014-10-31 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
PT3333188T (pt) 2010-08-19 2022-03-28 Zoetis Belgium S A Anticorpos de anti-ngf e a sua utilização
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
PE20140230A1 (es) 2010-08-20 2014-02-26 Novartis Ag Anticuerpos para el receptor del factor de crecimiento epidermico 3(her3)
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2012028703A1 (en) 2010-09-02 2012-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for the prognosis of the progression of cancer
MY162737A (en) 2010-09-09 2017-07-14 Pfizer 4-1bb binding molecules
WO2012032143A1 (en) 2010-09-10 2012-03-15 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
AU2011301803A1 (en) 2010-09-17 2013-03-21 Baxalta GmbH Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral pH
US9068014B2 (en) 2010-09-23 2015-06-30 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
US20120077691A1 (en) * 2010-09-24 2012-03-29 Full Spectrum Genetics, Inc. Method of analyzing binding interactions
ES2680624T3 (es) 2010-09-29 2018-09-10 Agensys, Inc. Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
SG10201508118WA (en) 2010-09-30 2015-11-27 Agency Science Tech & Res Methods and reagents for detection and treatment of esophageal metaplasia
EP2625203A1 (de) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1-antikörper und ihre verwendung zur behanldung von autoimmun- und entzündungserkrankungen
KR101920250B1 (ko) 2010-10-13 2018-11-20 얀센 바이오테크 인코포레이티드 인간 온코스타틴 m 항체 및 이용 방법
WO2012061120A1 (en) 2010-10-25 2012-05-10 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
WO2012061074A1 (en) 2010-10-25 2012-05-10 Elan Pharmaceuticals, Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
CA2816291C (en) 2010-10-29 2016-08-23 Daiichi Sankyo Company, Limited Anti-dr5 antibody
US9328160B2 (en) 2010-10-29 2016-05-03 Perseus Proteomics Inc. Anti-CDH3 antibody having high internalization capacity
EP2635674A4 (de) 2010-11-05 2014-11-05 Transbio Ltd Marker für endothelial-vorläuferzellen und verwendungen davon
WO2012065937A1 (en) 2010-11-15 2012-05-24 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
JP5904468B2 (ja) 2010-11-18 2016-04-13 国立大学法人 岡山大学 ヒト型抗体を産生するｂ細胞の作製方法
NZ609707A (en) 2010-11-19 2014-12-24 Morphosys Ag A collection and methods for its use
EP2643353A1 (de) 2010-11-24 2013-10-02 Novartis AG Multispezifische moleküle
WO2012069557A1 (en) 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
EP4279512A3 (de) 2010-11-30 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Zytotoxizitätsinduzierendes therapeutikum
CA2819356C (en) 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
KR20140003467A (ko) 2010-12-20 2014-01-09 메디뮨 리미티드 항il-18 항체 및 그의 용도
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
US8853365B2 (en) 2010-12-21 2014-10-07 Abbvie Inc. Dual variable domain immunnoglobulins and uses thereof
ES2720136T3 (es) 2010-12-22 2019-07-18 Teva Pharmaceuticals Australia Pty Ltd Anticuerpo modificado con semivida mejorada
CN103384831B (zh) 2010-12-23 2016-02-10 霍夫曼-拉罗奇有限公司 通过二价结合剂来检测多肽二聚体
JP6162044B2 (ja) 2010-12-23 2017-07-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 結合剤
JP6046049B2 (ja) 2010-12-23 2016-12-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二価結合剤による翻訳後修飾されたポリペプチドの検出
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JP2014504503A (ja) 2010-12-28 2014-02-24 ゾーマ テクノロジー リミテッド Ｐｄｚドメインを用いた細胞表面提示
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
SG191906A1 (en) 2011-01-14 2013-08-30 Ucb Pharma Sa Antibody molecules which bind il-17a and il-17f
WO2012102679A1 (en) 2011-01-24 2012-08-02 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
WO2012106615A1 (en) 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
US8952132B2 (en) 2011-02-07 2015-02-10 Research Development Foundation Engineered immunoglobulin FC polypeptides
KR20190089048A (ko) 2011-02-15 2019-07-29 이뮤노젠 아이엔씨 컨쥬게이트의 제조방법
BR112013021526B1 (pt) 2011-02-25 2021-09-21 Chugai Seiyaku Kabushiki Kaisha Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
EP2686016B1 (de) 2011-03-14 2019-05-01 Cellmid Limited Antikörper zur erkennung der n-domäne von midkin
EP2686014A1 (de) 2011-03-16 2014-01-22 Sanofi Verwendung eines antikörperähnlichen proteins mit dualer v-region
PL2691155T3 (pl) 2011-03-29 2019-06-28 Immunogen, Inc. Otrzymywanie koniugatu majtansynoidu przeciwciała jednoetapowym sposobem
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
WO2012138774A2 (en) 2011-04-04 2012-10-11 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
JP5908972B2 (ja) 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド 新規な抗原結合タンパク質
KR20140029446A (ko) 2011-04-15 2014-03-10 컴퓨젠 엘티디. 면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도
EP2700652B1 (de) 2011-04-18 2018-12-19 The University of Tokyo Diagnose und behandlung von krebs mittels anti-itm2a-antikörpern
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
EP2699597B1 (de) 2011-04-21 2016-06-01 Garvan Institute of Medical Research Modifizierte moleküle mit variablen domänen sowie herstellungs- und verwendungsverfahren dafür
RS57279B1 (sr) 2011-04-25 2018-08-31 Daiichi Sankyo Co Ltd Anti-b7-h3 antitelo
CN103732621B (zh) 2011-05-06 2020-04-24 內克斯威特澳大利亚私人有限公司 抗神经生长因子抗体及其制备和使用方法
MY160884A (en) 2011-05-06 2017-03-31 Nexvet Australia Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
ES2905682T3 (es) 2011-05-06 2022-04-11 Zoetis Services Llc Anticuerpos anti-factor de crecimiento nervioso y métodos de preparación y uso de los mismos
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
EP2708560A4 (de) 2011-05-09 2015-01-14 Perseus Proteomics Inc Antikörper zum spezifischen nachweis von transferrin-rezeptoren
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
MX358099B (es) 2011-05-17 2018-08-06 Univ Rockefeller Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.
NZ618016A (en) 2011-05-21 2015-05-29 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
AU2012260601B2 (en) 2011-05-25 2018-02-01 Innate Pharma, S.A. Anti-KIR antibodies for the treatment of inflammatory disorders
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2012168259A1 (en) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
CN104024275A (zh) 2011-06-10 2014-09-03 科里木恩有限公司 对于人β1-肾上腺素受体（β1-AR）的结合化合物以及它们在测量自身抗β1-AR抗体中的应用
ES2828482T3 (es) 2011-06-13 2021-05-26 Csl Ltd Anticuerpos contra el g-csfr y su uso
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
WO2012177837A2 (en) 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
LT2726094T (lt) 2011-06-28 2017-02-10 Oxford Biotherapeutics Ltd Gydymo ir diagnozavimo objektas
MY160826A (en) 2011-06-28 2017-03-31 Berlin-Chemie Ag Antibodies to bone marrow stromal antigen 1
US9428574B2 (en) 2011-06-30 2016-08-30 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
EP2728002B1 (de) 2011-06-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Heterodimerisiertes polypeptid
WO2013006437A1 (en) 2011-07-01 2013-01-10 Novartis Ag Method for treating metabolic disorders
JP2014520847A (ja) 2011-07-13 2014-08-25 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用して喘息を治療するための方法および組成物
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
EP2731970B1 (de) 2011-07-15 2018-11-28 MorphoSys AG Antikörper mit kreuzreaktion auf makrophagenmigrations-inhibitorfaktor (mif) und d-dopachrom-tautomerase (d-dt)
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP2736925A2 (de) 2011-07-27 2014-06-04 Glaxo Group Limited Mit fc-domänen fusionierbare anti-vegf-einzelvariablen-domänen
EP2756094B1 (de) 2011-08-15 2017-12-27 Medlmmune, LLC Anti-b7-h4 antikörper und ihre verwendungen
WO2013027802A1 (ja) 2011-08-23 2013-02-28 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
KR20140063752A (ko) 2011-08-30 2014-05-27 엔브이아이피 피티와이 리미티드 견화(犬化) 종양 괴사 인자 항체 및 그의 이용방법
EP2753697A1 (de) 2011-09-05 2014-07-16 ETH Zürich Biosynthetischer gencluster zur herstellung von peptid- bzw. protein-analoga
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
EP2753356B1 (de) 2011-09-09 2021-12-22 Medimmune Limited Anti-siglec-15 antikörper und ihre verwendungen
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
WO2013042426A1 (ja) 2011-09-21 2013-03-28 富士レビオ株式会社 親和性複合体に対する抗体
EA201790757A1 (ru) 2011-09-22 2017-07-31 Эмджен Инк. Связывающие антиген cd27l белки
PT2758073T (pt) 2011-09-23 2019-02-01 Oncomed Pharm Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
MX358827B (es) 2011-09-27 2018-09-05 Janssen Biotech Inc Supercóntigos de proteína basados en repeticiones de fibronectina tipo iii con superficies de unión alternativas.
CN108144058A (zh) 2011-09-30 2018-06-12 中外制药株式会社 促进抗原消除的抗原结合分子
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CA2850549C (en) 2011-09-30 2023-03-14 Teva Pharmaceuticals Australia Pty Ltd. Antibodies against tl1a and uses thereof
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CN110655578A (zh) 2011-09-30 2020-01-07 中外制药株式会社 诱导针对靶抗原的免疫应答的抗原结合分子
KR102276528B1 (ko) 2011-09-30 2021-07-12 추가이 세이야쿠 가부시키가이샤 이온 농도 의존성 결합 분자 라이브러리
WO2013051294A1 (ja) 2011-10-05 2013-04-11 中外製薬株式会社 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
US9575073B2 (en) 2011-10-10 2017-02-21 Rutgers, The State University Of New Jersey Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
EP3653222A1 (de) 2011-10-14 2020-05-20 Novartis AG Antikörper und verfahren für wnt-signalwegbedingte erkrankungen
RU2014120981A (ru) 2011-10-24 2015-12-10 Эббви Инк. Иммунные связывающие агенты против склеростина
AU2012327878A1 (en) 2011-10-28 2014-05-29 Patrys Limited PAT-LM1 epitopes and methods for using same
WO2013062083A1 (ja) 2011-10-28 2013-05-02 ファーマロジカルズ・リサーチ プライベート リミテッド 癌幹細胞特異的分子
ES2732712T3 (es) 2011-10-31 2019-11-25 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
JP2014533247A (ja) 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
EA201490926A1 (ru) 2011-11-04 2014-09-30 Новартис Аг Конструкции на основе белка, родственного липопротеинам низкой плотности, 6 (lrp6), и удлинителя полупериода существования
US20140314787A1 (en) 2011-11-08 2014-10-23 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Treatment for neurodegenerative diseases
WO2013068432A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Early diagnostic of neurodegenerative diseases
WO2013071233A1 (en) 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detecting infectious agents and a novel virus detected thereby
BR112014011304B1 (pt) 2011-11-11 2022-03-03 UCB Biopharma SRL Anticorpos de ligação com albumina e fragmentos de ligação dos mesmos, proteína de fusão de anticorpo bi-específico, polinucleotídeo, célula hospedeira, processo de produção de anticorpo ou fragamento do mesmo, formulação farmacêutica e uso
CA2856297C (en) 2011-11-23 2023-10-17 Medimmune, Llc Binding molecules specific for her3 and uses thereof
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
CA2857601A1 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
JP6243345B2 (ja) 2011-12-05 2017-12-06 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
WO2013090633A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CN104144947B (zh) 2011-12-14 2017-10-27 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
PE20150159A1 (es) 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
CN104159920A (zh) 2011-12-30 2014-11-19 艾伯维公司 针对il-13和/或il-17的双重可变结构域免疫球蛋白
EP2800583A1 (de) 2012-01-02 2014-11-12 Novartis AG Cdcp1 und brustkrebs
WO2013104798A1 (en) 2012-01-12 2013-07-18 Cemm - Center For Molecular Medicine Of The Austrian Academy Of Sciences Modulators of immune responses
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
DK2807192T3 (en) 2012-01-27 2018-07-23 Abbvie Deutschland COMPOSITION AND PROCEDURE FOR DIAGNOSTICATION AND TREATMENT OF DISEASES RELATED TO NEURITE DEGENERATION
RU2014111999A (ru) 2012-02-01 2016-03-27 Компуджен Лтд. Антитела к C10RF32 и их применения для лечения рака
US10633451B2 (en) 2012-02-03 2020-04-28 Hoffmann-La Roche Inc. Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
EP2812443B1 (de) 2012-02-06 2019-05-29 Inhibrx, Inc. Cd47-antikörper und verfahren zur verwendung davon
EP2813568A4 (de) 2012-02-09 2016-04-06 Chugai Pharmaceutical Co Ltd Modifizierte fc-antikörperregionen
BR112014019579A2 (pt) 2012-02-10 2019-10-15 Genentech, Inc Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
WO2013119990A2 (en) 2012-02-10 2013-08-15 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP2814842B1 (de) 2012-02-15 2018-08-22 Novo Nordisk A/S Antikörper die das peptidoglycan-erkennungs-protein erkennen
US9000127B2 (en) 2012-02-15 2015-04-07 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
TW202231872A (zh) 2012-02-24 2022-08-16 日商中外製藥股份有限公司 經FcγRIIB促進抗原消失之抗原結合分子
CA2867299C (en) 2012-03-15 2019-08-27 John Chen Human anti-cd27 antibodies, methods, and uses
EP2825557B1 (de) 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Manipuliertes lösliches monomeres fc
US9421250B2 (en) 2012-03-23 2016-08-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pathogenic phlebovirus isolates and compositions and methods of use
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013148232A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
WO2013147153A1 (ja) 2012-03-29 2013-10-03 株式会社未来創薬研究所 抗ｌａｍｐ５抗体およびその利用
WO2013144240A1 (en) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
US20150125470A1 (en) 2012-03-30 2015-05-07 Daiichi Sankyo Company, Limited Novel anti-siglec-15 antibody
AU2012376421A1 (en) 2012-04-04 2014-11-13 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (p-cadherin) antibody
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
EP2837685B1 (de) 2012-04-09 2020-09-09 Daiichi Sankyo Company, Limited Anti-fgfr2-antikörper
KR101950898B1 (ko) 2012-04-27 2019-02-22 다이이찌 산쿄 가부시키가이샤 항-robo4 항체
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
EP2849786B1 (de) 2012-05-15 2019-11-06 Eisai Inc. Verfahren zur behandlung von magenkrebs
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
BR112014029274B1 (pt) 2012-05-24 2022-02-15 Mountgate Innotech (Hk) Limited Anticorpo isolado, composição farmacêutica, uso do anticorpo, e, kit para tratar infecção rábica
US20150353630A1 (en) 2012-05-30 2015-12-10 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
TWI617578B (zh) 2012-05-30 2018-03-11 Chugai Pharmaceutical Co Ltd 標的組織專一的抗原結合分子
AU2013271515A1 (en) 2012-06-06 2015-01-15 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the Hippo pathway and uses thereof
EP2859018B1 (de) 2012-06-06 2021-09-22 Zoetis Services LLC Anti-ngf-antikörper für hunde und verfahren dafür
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
AU2013278075B2 (en) 2012-06-22 2018-05-17 Cytomx Therapeutics, Inc. Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof
BR112014032276A2 (pt) 2012-06-22 2017-11-28 King S College London construtos de vista-ig e o uso de vista-ig para o tratamento de distúrbios autoimunes, alérgicos e inflamatórios
EP2867254B1 (de) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Verfahren zum herstellen von antikörper-fc-region-konjugaten mit mindestens einer bindungsstelle, die spezifisch an ein target bindet, und verwendungen davon
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
CA2871386A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
WO2014001557A1 (en) 2012-06-28 2014-01-03 Ucb Pharma S.A. A method for identifying compounds of therapeutic interest
US20150218238A1 (en) 2012-06-29 2015-08-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear Treating diseases by modulating a specific isoform of mkl1
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
AR091755A1 (es) 2012-07-12 2015-02-25 Abbvie Inc Proteinas de union a il-1
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2880059A1 (de) 2012-08-02 2015-06-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Verwendung eines transferrin-rezeptorantagonisten zur behandlung von thalassämie
EP2887965A1 (de) 2012-08-22 2015-07-01 ImmunoGen, Inc. Zytotoxische benzodiazepin-derivate
EA032908B1 (ru) 2012-08-23 2019-08-30 Эдженсис, Инк. Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
ES2776681T3 (es) 2012-08-24 2020-07-31 Chugai Pharmaceutical Co Ltd Variante de la región Fc específica de FcgammaRIIb
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
RS60217B1 (sr) 2012-08-31 2020-06-30 Immunogen Inc Dijagnostički testovi i kompleti za detekciju folatnog receptora 1
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
AU2013312211B2 (en) 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
TWI606066B (zh) 2012-09-27 2017-11-21 中外製藥股份有限公司 FGFR3 Fusion Gene and Its Targeted Medicine
EP2904106A4 (de) 2012-10-01 2016-05-11 Univ Pennsylvania Zusammensetzungen und verfahren zum anzielung von stromazellen zur behandlung von krebs
NO2760138T3 (de) 2012-10-01 2018-08-04
JP6158933B2 (ja) 2012-10-03 2017-07-05 フィロゲン エスピーエー 炎症性腸疾患に関連する抗原
US10035817B2 (en) 2012-10-04 2018-07-31 Immunogen, Inc. Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane
KR102417310B1 (ko) 2012-10-11 2022-07-05 다이이찌 산쿄 가부시키가이샤 글리신아미드 화합물의 제조 방법
JP6356134B2 (ja) 2012-10-12 2018-07-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答の増強
BR112015008347B1 (pt) 2012-10-15 2023-12-26 Medimmune Limited Molécula de anticorpo, uso de dita molécula de anticorpo, composição para uso no tratamento de uma doença associada com betaamilóide, uso de uma composição, ácido nucleico, célula hospedeira e método para produção de uma molécula de anticorpo
EP2908912B1 (de) 2012-10-18 2020-08-05 The Rockefeller University Breit neutralisierende anti-hiv-antikörpern
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
JP6109952B2 (ja) 2012-11-01 2017-04-05 アッヴィ・インコーポレイテッド 抗ｖｅｇｆ／ｄｌｌ４二重可変ドメイン免疫グロブリンおよびこれらの使用
EP2914281A1 (de) 2012-11-05 2015-09-09 Genzyme Corporation Zusammensetzungen und verfahren zur behandlung von proteinopathien
PL2918603T3 (pl) 2012-11-08 2019-01-31 University Of Miyazaki Przeciwciało zdolne do specyficznego rozpoznawania receptora transferyny
JP6423357B2 (ja) 2012-11-21 2018-11-14 ヤンセン バイオテツク，インコーポレーテツド 二重特異性ＥＧＦＲ／ｃ−Ｍｅｔ抗体
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
HUE053669T2 (hu) 2012-12-05 2021-07-28 Novartis Ag Készítmények és eljárások EPO-t célzó antitestekre
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
JP6490591B2 (ja) 2012-12-10 2019-03-27 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗血液樹状細胞抗原２抗体およびその使用
WO2014099997A1 (en) 2012-12-18 2014-06-26 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
BR112015014482A2 (pt) 2012-12-18 2017-11-21 Icahn School Med Mount Sinai vacinas para vírus influenza e seus usos
JP6359031B2 (ja) 2012-12-21 2018-07-18 メディミューン，エルエルシー 抗ｈ７ｃｒ抗体
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
AU2013202668B2 (en) 2012-12-24 2014-12-18 Adelaide Research & Innovation Pty Ltd Inhibition of cancer growth and metastasis
KR102249779B1 (ko) 2012-12-27 2021-05-07 추가이 세이야쿠 가부시키가이샤 헤테로이량화 폴리펩티드
US9938344B2 (en) 2012-12-28 2018-04-10 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
KR102204127B1 (ko) 2013-02-01 2021-01-20 키라 바이오테크 피티와이 리미티드 항-cd83 항체 및 이의 용도
KR102170196B1 (ko) 2013-02-06 2020-10-26 인히브릭스, 인크. 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
JP6545105B2 (ja) 2013-02-07 2019-07-17 シーエスエル、リミテッド Ｉｌ−１１ｒ結合タンパク質及びその使用
HUE047119T2 (hu) 2013-02-08 2020-04-28 Novartis Ag Anti-IL-17A antitestek és alkalmazásaik autoimmun és gyulladásos betegségek kezelésében
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
JP6423804B2 (ja) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
EP2962100B1 (de) 2013-02-28 2021-07-28 Caprion Proteomics Inc. Tuberkulose biomarker und deren verwendung
US9999680B2 (en) 2013-02-28 2018-06-19 Immunogen, Inc. Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
MX362075B (es) 2013-03-14 2019-01-07 Abbott Lab Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
US10093921B2 (en) 2013-03-14 2018-10-09 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
US9790478B2 (en) 2013-03-14 2017-10-17 Abbott Laboratories HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
CN105378099B (zh) 2013-03-14 2021-05-11 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
CA2904527A1 (en) 2013-03-15 2014-09-18 Abbvie Biotechnology Ltd. Anti-cd25 antibodies and their uses
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
EP2970436B1 (de) 2013-03-15 2018-09-05 AbbVie Biotherapeutics Inc. Fc-varianten
EP3216804A3 (de) 2013-03-15 2017-12-20 AbbVie Biotechnology Ltd. Anti-cd25-antikörper und deren verwendungen
SG10201800313UA (en) 2013-03-15 2018-02-27 Abbvie Inc Antibody drug conjugate (adc) purification
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
EP2970461A4 (de) 2013-03-15 2016-11-23 Janssen Biotech Inc Interferon-alpha- und omega-antikörper-antagonisten
TW201945032A (zh) 2013-03-15 2019-12-01 德商艾伯維德國有限及兩合公司 抗-egfr抗體藥物結合物調配物
CA2903546A1 (en) 2013-03-15 2014-09-25 Biogen Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
SG10201708048XA (en) 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
KR20210157418A (ko) 2013-03-27 2021-12-28 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP3783017A1 (de) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Varianten der fc-region
PT2981822T (pt) 2013-05-06 2020-12-07 Scholar Rock Inc Composições e métodos para modulação do fator de crescimento
CN107095872A (zh) 2013-05-16 2017-08-29 国立大学法人京都大学 用于确定癌症预后的方法
SG11201509618QA (en) 2013-05-24 2015-12-30 Medimmune Llc Anti-b7-h5 antibodies and their uses
HUE040548T2 (hu) 2013-05-30 2019-03-28 Kiniksa Pharmaceuticals Ltd Onkosztatin-M-receptor antigénjét kötõ fehérjék
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
EP3632467B1 (de) 2013-06-07 2023-09-27 Duke University Inhibitoren des komplementfaktors h
JP6442404B2 (ja) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
WO2014208482A1 (ja) 2013-06-24 2014-12-31 中外製薬株式会社 ヒト化抗Ｅｐｉｒｅｇｕｌｉｎ抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
EP3013422A1 (de) 2013-06-28 2016-05-04 Amgen Inc. Verfahren zur behandlung von homozygoter familiärer hypercholesterolämie
EP3022295A4 (de) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signatur des tl1a (tnfsf15)-signalweges
RU2679657C2 (ru) 2013-08-01 2019-02-12 Эдженсис, Инк. Конъюгаты антител с лекарственными средствами, связывающиеся с белками cd37
KR101809072B1 (ko) 2013-08-02 2017-12-14 화이자 인코포레이티드 항-cxcr4 항체 및 항체-약물 접합체
CN104341504B (zh) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
ES2761587T3 (es) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
WO2015023851A1 (en) 2013-08-14 2015-02-19 The Governing Council Of The University Of Toronto Antibodies against frizzled proteins and methods of use thereof
AU2014307589A1 (en) 2013-08-14 2016-02-11 Novartis Ag Methods of treating sporadic inclusion body myositis
EP3036320B2 (de) 2013-08-19 2024-04-03 Biogen MA Inc. Steuerung der proteinglykosylierung durch kulturmediumsupplementation und zellkulturprozessparametern
CN112695039A (zh) 2013-08-26 2021-04-23 生物技术研发公司 编码抗唾液酸化路易斯a抗原的人抗体的核酸
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
WO2015034052A1 (ja) 2013-09-05 2015-03-12 国立大学法人 宮崎大学 ヒトインテグリンａ６ｂ４と特異的に反応する抗体
US20160229922A1 (en) 2013-09-20 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Treatment for hemorrhagic diseases by anti-protein-c antibody
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CA2925897A1 (en) 2013-09-30 2015-04-02 Daiichi Sankyo Company, Limited Anti-lps o11 antibody
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
KR102501920B1 (ko) 2013-10-02 2023-02-20 메디뮨 엘엘씨 중화 항-인플루엔자 a 항체 및 이의 용도
KR20220136468A (ko) 2013-10-08 2022-10-07 이뮤노젠 아이엔씨 항-folr1 면역접합체 투여 레지멘
ES2768618T3 (es) 2013-10-08 2020-06-23 Daiichi Sankyo Co Ltd Combinación de anticuerpo anti-FGFR2 y otro agente
EP3057608A4 (de) 2013-10-14 2017-10-11 Janssen Biotech, Inc. Mit cystein manipulierte fibronectin-typ-iii-domänenbindungsmoleküle
CN111443069A (zh) 2013-10-28 2020-07-24 多茨技术公司 过敏原检测
US9840555B2 (en) 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
ES2884255T3 (es) 2013-11-06 2021-12-10 Janssen Biotech Inc Anticuerpos anti-CCL17
CN105940107B (zh) 2013-11-11 2021-06-15 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
EP3074038B1 (de) 2013-11-28 2019-01-02 CSL Limited Verfahren zur behandlung der diabetischen nephropathie
TWI702316B (zh) 2013-12-04 2020-08-21 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
CN105980405A (zh) 2013-12-08 2016-09-28 派特塞尔有限公司 Hiv抗原和抗体及其组合物、方法和用途
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
KR20160096194A (ko) 2013-12-18 2016-08-12 씨에스엘 리미티드 상처 치료 방법
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
DK3087098T3 (da) 2013-12-24 2020-06-08 Janssen Pharmaceutica Nv Anti-Vista-antistoffer og -fragmenter
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR102088169B1 (ko) 2013-12-25 2020-03-12 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
WO2015099127A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
AU2014370873B2 (en) 2013-12-27 2020-06-11 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
CN110464847B (zh) 2014-01-31 2024-02-09 第一三共株式会社 抗her2抗体－药物偶联物
WO2015127134A2 (en) 2014-02-20 2015-08-27 Allergan, Inc. Complement component c5 antibodies
EP3110845A1 (de) 2014-02-27 2017-01-04 Allergan, Inc. Komplementfaktor-bb-antikörper
CN106414465B (zh) 2014-02-28 2021-11-16 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
EP3122869B2 (de) 2014-03-24 2022-08-10 Biogen MA Inc. Verfahren zur überwindung von glutamindeprivation bei einer säugetierzellkultur
WO2015150900A2 (en) 2014-03-31 2015-10-08 Debiopharm International Sa Fgfr fusions
EP3126397B1 (de) 2014-04-04 2020-01-29 Bionomics, Inc. Humanisierte antikörper zur bindung von lgr5
PT3128997T (pt) 2014-04-08 2020-09-04 Boston Pharmaceuticals Inc Moléculas de ligação específicas para il-21 e suas utilizações
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
JP2017512765A (ja) 2014-04-11 2017-05-25 メディミューン，エルエルシー 二重特異性ｈｅｒ２抗体
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
AU2015249946A1 (en) 2014-04-25 2016-11-17 The Brigham And Women's Hospital Inc. Methods to manipulate alpha-fetoprotein (AFP)
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
JP6832709B2 (ja) 2014-05-16 2021-02-24 メディミューン，エルエルシー 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子
IL249092B (en) 2014-05-28 2022-07-01 Agenus Inc Anti-gitr antibodies and methods of using them
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
ES2863074T3 (es) 2014-06-04 2021-10-08 Biontech Res And Development Inc Anticuerpos monoclonales humanos contra el gangliósido GD2
EA037006B1 (ru) 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
WO2015191881A2 (en) 2014-06-11 2015-12-17 Green Kathy A Use of vista agonists and antagonists to suppress or enhance humoral immunity
WO2015189816A1 (en) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research New treatment against influenza virus
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
EP3157535A1 (de) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Verfahren zur auslösung der novo-bildung von heterochromatin und/oder zur epigenetischen abschaltung mit kleinen rnas
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
EP3160990A2 (de) 2014-06-25 2017-05-03 Novartis AG Zusammensetzungen und verfahren für proteine mit langer wirkung
EP3161001A2 (de) 2014-06-25 2017-05-03 Novartis AG Il17-a spezifische antikörper die mit hyaluronan bindenden peptid-marker fusioniert sind
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US10273311B2 (en) 2014-06-26 2019-04-30 Yale University Compositions to regulate renalase in the treatment of diseases and disorders
WO2016001830A1 (en) 2014-07-01 2016-01-07 Friedrich Miescher Institute For Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US10179814B2 (en) 2014-07-17 2019-01-15 Novo Nordisk A/S Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
PL3177642T3 (pl) 2014-08-07 2022-03-07 Novartis Ag Przeciwciała angiopoetynopodobne 4 i sposoby stosowania
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
US20170362304A1 (en) 2014-08-20 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
EP3189057A1 (de) 2014-09-03 2017-07-12 ImmunoGen, Inc. Zytotoxische benzodiazepin-derivate
US9669102B2 (en) 2014-09-03 2017-06-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
CN107073135B (zh) 2014-09-08 2023-06-06 鲁塔纳有限公司 用于将分子递送至细胞的细胞质中的构建体
MX2017003115A (es) 2014-09-09 2017-11-17 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38.
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI707870B (zh) 2014-10-01 2020-10-21 英商梅迪繆思有限公司 針對替格瑞洛的抗體及使用方法
JP2017531642A (ja) 2014-10-03 2017-10-26 マサチューセッツ インスティテュート オブ テクノロジー エボラ糖タンパク質に結合する抗体およびその使用
MA41685A (fr) 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
CA2965170A1 (en) 2014-10-23 2016-04-28 Dendrocyte Biotech Pty Ltd Cd83 binding proteins and uses thereof
AU2015336946A1 (en) 2014-10-23 2017-04-13 La Trobe University Fn14-binding proteins and uses thereof
AU2015339012B2 (en) 2014-10-31 2020-11-05 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
WO2016073401A1 (en) 2014-11-03 2016-05-12 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
DK3218406T3 (da) 2014-11-10 2021-06-21 Medimmune Ltd Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf
EP3789403A1 (de) 2014-11-11 2021-03-10 MedImmune Limited Therapeutische kombinationen mit anti-cd73-antikörpern und a2a-rezeptorinhibitoren sowie verwendungen davon
CA2967595A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN107406503B (zh) 2014-11-18 2021-07-16 詹森药业有限公司 Cd47抗体、方法和用途
MA40934A (fr) 2014-11-19 2017-09-27 Immunogen Inc Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
EP3221340A1 (de) 2014-11-19 2017-09-27 Koninklijke Philips N.V. Diagnoseverfahren mit hnl
EP3220900B1 (de) 2014-11-21 2020-09-23 University of Maryland, Baltimore Systeme zur gezielten strukturspezifischen partikelabgabe
PT3221363T (pt) 2014-11-21 2020-07-23 Bristol Myers Squibb Co Anticorpos contra cd73 e utilizações dos mesmos
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
WO2016090347A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
WO2016094425A1 (en) 2014-12-08 2016-06-16 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
JP2018506509A (ja) 2014-12-09 2018-03-08 アッヴィ・インコーポレイテッド 細胞透過性Ｂｃｌ−ｘＬ阻害剤との抗体薬物コンジュゲート
US20160339117A1 (en) 2014-12-09 2016-11-24 Abbvie Inc. BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same
DK3229838T3 (da) 2014-12-11 2020-10-19 Pf Medicament Anti-C10orf54-antistoffer og anvendelser deraf
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
US10940212B2 (en) 2014-12-19 2021-03-09 Monash University IL-21 agonist antibodies and methods of treatment using same
JP6738348B2 (ja) 2014-12-19 2020-08-12 リジェネサンス ベスローテン フェンノートシャップ ヒトｃ６に結合する抗体およびその使用
CA2972048C (en) 2014-12-22 2023-03-07 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
SG10202006538TA (en) 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
GB2557389B (en) 2015-01-14 2020-12-23 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
WO2016118937A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
KR102590740B1 (ko) 2015-02-02 2023-10-18 칠드런스 헬스 케어 디/비/에이 칠드런스 미네소타 항-대리 경쇄 항체
US10457737B2 (en) 2015-02-09 2019-10-29 Research Development Foundation Engineered immunoglobulin Fc polypeptides displaying improved complement activation
EP3271388A1 (de) 2015-02-09 2018-01-24 INSERM - Institut National de la Santé et de la Recherche Médicale Spezifische antikörper gegen glykoprotein (gp) des ebolavirus und verwendungen zur behandlung und diagnose von ebolavirusinfektion
TWI805046B (zh) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
DE112016001013T5 (de) 2015-03-03 2017-12-21 Kymab Limited Antikörper, verwendungen und verfahren
WO2016142288A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
EP3268100A1 (de) 2015-03-13 2018-01-17 Bristol-Myers Squibb Company Verwendung von alkalischen spülungen während der chromatografie während zum entfernen von verunreinigungen
JP6968698B2 (ja) 2015-03-17 2021-11-24 メモリアル スローン ケタリング キャンサー センター 抗ｍｕｃ１６抗体及びその使用
US20180105555A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran for protein purification
WO2016153978A1 (en) 2015-03-20 2016-09-29 Bristol-Myers Squibb Company Use of dextran to enhance protein purification by affinity chromatography
EP3274468B1 (de) 2015-03-25 2019-02-20 Alexion Pharmaceuticals, Inc. Verfahren zur bestimmung der c3- und c5- konvertase protease-aktivität im alternativen komplement-pfad
WO2016151558A1 (en) 2015-03-25 2016-09-29 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
US11136401B2 (en) 2015-03-27 2021-10-05 University Of Southern California Car t-cell therapy directed to LHR for the treatment of solid tumors
EP3733701A1 (de) 2015-03-31 2020-11-04 MedImmune Limited Neuartige il33-form, mutierte formen von il33, antikörper, tests und verfahren zur verwendung davon
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
US10814012B2 (en) 2015-04-29 2020-10-27 University Of South Australia Compositions and methods for administering antibodies
JP2018514573A (ja) 2015-05-01 2018-06-07 メディミューン リミテッド 新規のファージディスプレイライブラリ、そのメンバーおよびその使用
CN107849116A (zh) 2015-05-06 2018-03-27 詹森生物科技公司 前列腺特异性膜抗原结合iii型纤连蛋白结构域
MA42059A (fr) 2015-05-06 2018-03-14 Janssen Biotech Inc Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
TWI820377B (zh) 2015-05-07 2023-11-01 美商艾吉納斯公司 抗ｏｘ４０抗體及其使用方法
EP4292664A2 (de) 2015-05-15 2023-12-20 The General Hospital Corporation Antagonistische anti-tumor-nekrosefaktorrezeptorsuperfamilienantikörper
EP3095465A1 (de) 2015-05-19 2016-11-23 U3 Pharma GmbH Kombination von fgfr4-inhibitor und gallensäurekomplexbildner
JP6827426B2 (ja) 2015-05-20 2021-02-10 ヤンセン バイオテツク，インコーポレーテツド 軽鎖アミロイドーシス及びその他のｃｄ３８陽性血液悪性疾患の治療のための抗ｃｄ３８抗体
WO2016189045A1 (en) 2015-05-27 2016-12-01 Ucb Biopharma Sprl Method for the treatment of neurological disease
US10174121B2 (en) 2015-05-29 2019-01-08 Abbvie, Inc. Anti-CD40 antibodies
SG10201913500TA (en) 2015-05-29 2020-03-30 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
US20180237534A1 (en) 2015-05-29 2018-08-23 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
CA2987992A1 (en) 2015-06-04 2016-12-08 University Of Southern California Lym-1 and lym-2 targeted car cell immunotherapy
JP2018522540A (ja) 2015-06-05 2018-08-16 ノバルティス アーゲー 骨形成タンパク質９（ｂｍｐ９）を標的とする抗体およびそれらのための方法
US10723793B2 (en) 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
AU2016282674B2 (en) 2015-06-22 2022-01-13 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
DK3313441T3 (da) 2015-06-24 2024-04-15 Janssen Biotech Inc Immunmodulering og behandling af faste tumorer med antistoffer, der specifikt binder cd38
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
EP3313886A1 (de) 2015-06-29 2018-05-02 The Rockefeller University Antikörper gegen cd40 mit erhöhter agonistischer aktivität
BR112017027690A2 (pt) 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
JP7203497B2 (ja) 2015-06-29 2023-01-13 イミュノジェン・インコーポレーテッド 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体
CN113350518A (zh) 2015-07-12 2021-09-07 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
AU2016303545B2 (en) 2015-08-03 2019-09-12 Novartis Ag Methods of treating FGF21-associated disorders
MX2018001522A (es) 2015-08-05 2018-03-15 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos.
US11384138B2 (en) 2015-08-19 2022-07-12 Rutgers, The State University Of New Jersey Methods of generating antibodies
PE20181322A1 (es) 2015-09-01 2018-08-14 Agenus Inc Anticuerpo anti-pd1 y sus metodos de uso
RU2731644C2 (ru) 2015-09-09 2020-09-07 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
AU2016319126A1 (en) * 2015-09-10 2018-04-19 Affigen, Inc. Sequencing-directed selection of tumor theranostics
CN108601828B (zh) 2015-09-17 2023-04-28 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
EP3569244A1 (de) 2015-09-23 2019-11-20 CytoImmune Therapeutics, LLC Flt3-gerichtete car-zellen zur immuntherapie
JP6959912B2 (ja) 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
BR112018005777A2 (pt) 2015-09-24 2018-10-09 Daiichi Sankyo Company, Limited anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produzir um anticorpo de interesse ou um fragmento do mesmo composição farmacêutica, e, uso de pelo menos um anticorpo
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
EP3355921A4 (de) 2015-09-30 2019-05-22 Janssen Biotech, Inc. Antagonistische antikörper, die spezifisch an menschliches cd40 binden, und verfahren zur verwendung
SG10202112586WA (en) 2015-10-27 2021-12-30 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
EP3368566A1 (de) 2015-10-28 2018-09-05 Friedrich Miescher Institute for Biomedical Research Tenascin-w und gallengangkrebs
LT3827845T (lt) 2015-11-03 2022-06-10 Janssen Biotech, Inc. Poodinės anti-cd38 antikūnų kompozicijos ir jų naudojimas
BR112018008904A2 (pt) 2015-11-03 2018-11-27 Janssen Biotech Inc anticorpos que se ligam especificamente a tim-3 e seus usos
EP3374398B1 (de) 2015-11-10 2020-03-18 MedImmune, LLC Für asct2 spezifische bindemoleküle und verwendungen davon
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3378487B1 (de) 2015-11-18 2022-03-16 Chugai Seiyaku Kabushiki Kaisha Kombinationstherapie mit t-zell-neuausrichtendem antigenbindendem molekül gegen zelle mit immunsuppressiver funktion
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11208483B2 (en) 2015-11-19 2021-12-28 Shanghai Kanda Biotechnology Co, Ltd. CTLA-4 antibodies and uses thereof
EA201891121A1 (ru) 2015-11-19 2018-12-28 Бристол-Майерс Сквибб Компани Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
WO2017095823A1 (en) 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
WO2017095805A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
US10556948B2 (en) 2015-11-30 2020-02-11 Bristol-Myers Squibb Company IP-10 antibodies and their uses
EP3383910A1 (de) 2015-11-30 2018-10-10 AbbVie Inc. Anti-hulrrc15-antikörper-wirkstoff-konjugate und verfahren zu deren verwendung
CA3006769A1 (en) 2015-12-02 2017-06-08 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
EP3386542B1 (de) 2015-12-10 2020-11-18 Katholieke Universiteit Leuven Anti-adamts13-antikörper und deren verwendung zur behandlung oder verhütung von hämorrhagischen störungen aufgrund einer ventrikulären unterstützungsvorrichtung
BR112018012344A2 (pt) 2015-12-17 2018-12-04 Janssen Biotech Inc anticorpos que se ligam especificamente a hla-dr e seus usos
UY37030A (es) 2015-12-18 2017-07-31 Novartis Ag Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
EP3184544A1 (de) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein-v-inhibitoren zur verwendung als koagulansien
KR20180100132A (ko) 2016-01-08 2018-09-07 이온타스 엘티디 변형된 다양성 스캐폴드 도메인을 갖는 결합 멤버
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
EP3851457A1 (de) 2016-01-21 2021-07-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
CA3013125A1 (en) 2016-02-05 2017-08-10 Immunogen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
CN109069626A (zh) 2016-02-12 2018-12-21 詹森药业有限公司 抗-vista(b7h5)抗体
WO2017143062A1 (en) 2016-02-16 2017-08-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
EP3423494A1 (de) 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Kombinationstherapie mit anti-cd73-antikörpern
EA201891925A1 (ru) 2016-03-04 2019-02-28 Зэ Рокфеллер Юниверсити Антитела к cd40 с усиленной агонистической активностью
KR102603010B1 (ko) 2016-03-10 2023-11-16 비엘라 바이오, 인크. Ilt7 결합 분자 및 이의 사용 방법
KR102457751B1 (ko) 2016-03-10 2022-10-21 악셀레론 파마 인코포레이티드 액티빈 타입 2 수용체 결합 단백질 및 이의 용도
KR20180116215A (ko) 2016-03-14 2018-10-24 추가이 세이야쿠 가부시키가이샤 암의 치료에 이용하기 위한 세포상해 유도 치료제
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
KR102413037B1 (ko) 2016-03-15 2022-06-23 메르사나 테라퓨틱스, 인코포레이티드 Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법
JP2019508473A (ja) 2016-03-16 2019-03-28 メリマック ファーマシューティカルズ インコーポレーティッド 標的ドセタキセル産生ナノリポソーム組成物を用いたエフリン受容体Ａ２（ＥｐｈＡ２）陽性癌の治療
JP2019508434A (ja) 2016-03-16 2019-03-28 メリマック ファーマシューティカルズ インコーポレーティッド エフリン受容体Ａ２（ＥｐｈＡ２）標的ドセタキセル産生ナノリポソーム組成物
MA43715A (fr) 2016-03-17 2018-11-28 Numab Innovation Ag Anticorps anti-tnf et fragments fonctionnels correspondants
MA43716A (fr) 2016-03-17 2018-11-28 Numab Innovation Ag Anticorps anti-tnf et fragments fonctionnels de ceux-ci
RS61412B1 (sr) 2016-03-17 2021-03-31 Tillotts Pharma Ag Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
PL3219726T3 (pl) 2016-03-17 2021-07-19 Tillotts Pharma Ag Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty
SG11201808041UA (en) 2016-03-17 2018-10-30 Numab Innovation Ag ANTI-TNFa-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
AU2017239038A1 (en) 2016-03-22 2018-10-04 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody
CA3019164A1 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017181139A2 (en) 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof
CN116059351A (zh) 2016-04-18 2023-05-05 塞德斯医疗公司 结合人cd40的激动性抗体及其用途
SG11201809793UA (en) 2016-05-09 2018-12-28 Bristol Myers Squibb Co Tl1a antibodies and uses thereof
US20170348429A1 (en) 2016-05-17 2017-12-07 Abbvie Biotherapeutics Inc. ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
WO2017205465A2 (en) 2016-05-24 2017-11-30 Griswold Karl Edwin Antibodies and methods of making same
WO2017205721A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
EP3464362B1 (de) 2016-05-27 2020-12-09 AbbVie Biotherapeutics Inc. Anti-4-1bb-antikörper und deren verwendungen
ES2901722T3 (es) 2016-05-27 2022-03-23 Abbvie Biotherapeutics Inc Anticuerpos anti-CD40 y sus usos
UY37269A (es) 2016-06-02 2018-01-02 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
US10925932B2 (en) 2016-06-03 2021-02-23 Janssen Biotech, Inc. Serum albumin-binding fibronectin type III domains
RS61828B1 (sr) 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antitela i antitelske konjugacije lekova
LT3368069T (lt) 2016-06-13 2020-12-10 Scholar Rock, Inc. Miostatino inhibitorių naudojimas, ir kombinuotas gydymas
EP3471759A1 (de) 2016-06-15 2019-04-24 Novartis AG Verfahren zur behandlung einer erkrankung mithilfe von inhibitoren von knochenmorphogenetischem protein 6 (bmp6)
EP3471767A4 (de) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenzavirus-hämagglutinin-proteine und verwendungen davon
EA201990067A1 (ru) 2016-06-21 2019-07-31 Янссен Байотек, Инк. Цистеин-модифицированные связывающие молекулы на основе домена фибронектина iii типа
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
EP3481862A4 (de) 2016-07-06 2020-08-12 Celgene Corporation Antikörper mit geringer immunogenität und verwendungen davon
WO2018009834A1 (en) 2016-07-07 2018-01-11 Berg Llc Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
PE20190418A1 (es) 2016-07-14 2019-03-19 Bristol Myers Squibb Co Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
KR20190063458A (ko) 2016-07-15 2019-06-07 포세이다 테라퓨틱스, 인크. Ｍｕｃ1에 특이적인 키메라 항원 수용체(ｃａｒｓ) 및 그의 사용 방법
EP3484914A1 (de) 2016-07-15 2019-05-22 Poseida Therapeutics, Inc. Chimäre antigenrezeptoren und verfahren zur verwendung
EP3487506A1 (de) 2016-07-20 2019-05-29 Hybrigenics SA Kombinationen von inecalcitol mit einem anti-cd38-mittel und deren verwendungen zur behandlung von krebs
EP3487886A2 (de) 2016-07-22 2019-05-29 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Trem2-spaltungsmodulatoren und verwendungen davon
EP3487880A1 (de) 2016-07-25 2019-05-29 Biogen MA Inc. Anti-hspa5(grp78)-antikörper und verwendungen davon
CN109661406A (zh) 2016-07-29 2019-04-19 国家医疗保健研究所 靶向肿瘤相关巨噬细胞的抗体及其用途
EA201990222A1 (ru) 2016-08-05 2019-07-31 МЕДИММЬЮН, ЭлЭлСи Антитела к o2 и пути их применения
AU2017308590A1 (en) 2016-08-12 2019-02-14 Janssen Biotech, Inc. Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
CA3033665A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
US10947268B2 (en) 2016-08-12 2021-03-16 Bristol-Myers Squibb Company Methods of purifying proteins
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
SI3512547T1 (sl) 2016-09-14 2021-01-29 Abbvie Biotherapeutics Inc. Anti-PD-1 protitelesa
CA3036972A1 (en) 2016-09-14 2018-03-22 Janssen Biotech, Inc. Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
WO2018053597A1 (en) 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
MA46366A (fr) 2016-09-30 2019-08-07 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
CN110249226B (zh) 2016-10-03 2023-08-25 雅培实验室 评估患者样品中gfap状态的改进方法
SG10201912173RA (en) 2016-10-07 2020-02-27 Daiichi Sankyo Co Ltd Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
JP2020500007A (ja) 2016-10-13 2020-01-09 マサチューセッツ インスティテュート オブ テクノロジー ジカウイルスエンベロープタンパク質に結合する抗体およびその使用
EP3312290A1 (de) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Zellulärer vamp-spaltungstest
AU2017346488A1 (en) 2016-10-19 2019-05-30 Humabs Biomed Sa Anti-O1 antibodies and uses thereof
SG11201903737PA (en) 2016-10-26 2019-05-30 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
RU2019114863A (ru) 2016-11-02 2020-12-03 Иммуноджен, Инк. Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
WO2018083240A1 (en) 2016-11-03 2018-05-11 Roche Diagnostics Gmbh Novel anti-py796-ddr1 antibodies
WO2018083238A1 (en) 2016-11-03 2018-05-11 Roche Diagnostics Gmbh Novel anti-py792-ddr1 antibodies
WO2018083237A1 (en) 2016-11-03 2018-05-11 Roche Diagnostics Operations Inc. Novel anti-py520-ddr1 antibodies
WO2018083235A1 (en) 2016-11-03 2018-05-11 Roche Diagnostics Gmbh Novel anti-py513-ddr1 antibodies
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
JP7045724B2 (ja) 2016-11-07 2022-04-01 ニューラクル サイエンス カンパニー リミテッド 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
NZ754407A (en) 2016-11-09 2023-01-27 Philogen Spa Il2 and tnf mutant immunoconjugates
EP3538550A1 (de) 2016-11-10 2019-09-18 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Or10h1-modulatoren und verwendungen davon
EP3538546A1 (de) 2016-11-14 2019-09-18 Novartis AG Zusammensetzungen, verfahren und therapeutische verwendungen im zusammenhang mit fusogenem protein minion
NZ752394A (en) 2016-11-14 2021-07-30 Hangzhou Dac Biotech Co Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
KR20190078648A (ko) 2016-11-16 2019-07-04 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 방법
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
KR102532256B1 (ko) 2016-11-21 2023-05-12 쿠레아브 게엠베하 항-gp73　항체　및　면역접합체
US20230192896A1 (en) 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
US20200207846A1 (en) 2016-11-28 2020-07-02 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
WO2018106864A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
AU2017378226A1 (en) 2016-12-14 2019-06-20 Janssen Biotech, Inc. CD8A-binding fibronectin type III domains
EP3554561B1 (de) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137-bindende fibronectin-typ-iii-domänen
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
CN110573527A (zh) 2016-12-15 2019-12-13 艾伯维生物制药股份有限公司 抗ox40抗体及其用途
CA3043624A1 (en) 2016-12-16 2018-06-21 Merck Patent Gmbh Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
SG10201912366YA (en) 2016-12-22 2020-02-27 Daiichi Sankyo Co Ltd Anti-cd3 antibody and molecules comprising the antibody
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
WO2018129395A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
AU2018205270B2 (en) 2017-01-06 2022-08-11 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
US20180244785A1 (en) 2017-01-09 2018-08-30 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
TWI780104B (zh) 2017-01-17 2022-10-11 日商第一三共股份有限公司 抗ｇｐｒ２０抗體及抗ｇｐｒ２０抗體-藥物結合物、以及其製造方法及用途
KR20240038146A (ko) 2017-01-30 2024-03-22 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
KR20190133160A (ko) 2017-02-07 2019-12-02 다이이찌 산쿄 가부시키가이샤 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
KR20190115042A (ko) 2017-02-07 2019-10-10 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
KR102572663B1 (ko) 2017-02-08 2023-09-01 노파르티스 아게 Fgf21 모방 항체 및 이의 용도
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
CN116785450A (zh) 2017-02-28 2023-09-22 伊缪诺金公司 具有自分解肽接头的类美登素衍生物和其缀合物
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
BR112019018043A2 (pt) 2017-03-03 2020-04-07 Seattle Genetics Inc método de tratamento de câncer, e, conjugado de anticorpo-fármaco
SG11201908418RA (en) 2017-03-13 2019-10-30 Poseida Therapeutics Inc Compositions and methods for selective elimination and replacement of hematopoietic stem cells
JP7346300B2 (ja) 2017-03-23 2023-09-19 アボット・ラボラトリーズ 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
WO2018174274A1 (ja) 2017-03-24 2018-09-27 全薬工業株式会社 抗ＩｇＭ／Ｂ細胞表面抗原二重特異性抗体
CA3054837A1 (en) 2017-03-24 2018-09-27 Novartis Ag Methods for preventing and treating heart disease
KR20230148855A (ko) 2017-03-30 2023-10-25 더 존스 홉킨스 유니버시티 생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템
EP3606555A4 (de) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai Neuraminidase-antikörper gegen influenza-b-virus und verwendungen davon
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
MX2019012223A (es) 2017-04-13 2019-12-09 Agenus Inc Anticuerpos anti-cd137 y metodos de uso de los mismos.
CA3053409A1 (en) 2017-04-15 2018-10-18 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
US20180346488A1 (en) 2017-04-20 2018-12-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
KR20190141659A (ko) 2017-04-21 2019-12-24 스태튼 바이오테크놀로지 비.브이. 항-apoc3 항체 및 이의 사용 방법
JP2020517271A (ja) 2017-04-22 2020-06-18 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 改良ｌａｍｐ構築物
WO2018200823A1 (en) 2017-04-28 2018-11-01 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
IL297073B2 (en) 2017-05-02 2023-12-01 Immunomic Therapeutics Inc LAMP constructs containing cancer antigens
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
AU2018275235A1 (en) 2017-05-30 2019-10-31 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
US20200148768A1 (en) 2017-05-31 2020-05-14 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
US11149094B2 (en) 2017-06-05 2021-10-19 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
EP3634999A1 (de) 2017-06-07 2020-04-15 Philogen S.p.A. Gefässendothelwachstumsfaktor-/antifibronectin-antikörper-fusionsproteine
GB201709379D0 (en) 2017-06-13 2017-07-26 Univ Leuven Kath Humanised ADAMTS13 binding antibodies
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2019003104A1 (en) 2017-06-28 2019-01-03 Novartis Ag METHOD FOR PREVENTING AND TREATING URINARY INCONTINENCE
US20200115446A1 (en) 2017-06-30 2020-04-16 National University Corporation Hokkaido University Pediatric osteoporosis drug that does not cause growth disorder
US11169159B2 (en) 2017-07-03 2021-11-09 Abbott Laboratories Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood
CA3069438A1 (en) 2017-07-11 2019-01-17 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
WO2019012015A1 (en) 2017-07-12 2019-01-17 Iontas Limited POTASIC CHANNEL INHIBITORS
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
BR112020000386A2 (pt) 2017-07-13 2020-07-21 F. Hoffmann-La Roche Ag agente de ligação específico, anticorpo monoclonal, métodos de detecção de pivka-ii, método diagnóstico do carcinoma hepatocelular, uso de um agente de ligação específico e kit
WO2019020480A1 (en) 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
SG11202000634UA (en) 2017-07-27 2020-02-27 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
TW202402805A (zh) 2017-07-27 2024-01-16 日商第一三共股份有限公司 抗cd147抗體、醫藥組成物、該等之用途及抗cd147抗體之製造方法
US20200231682A1 (en) 2017-07-28 2020-07-23 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
EP3444275A1 (de) 2017-08-16 2019-02-20 Exiris S.r.l. Monoklonaler antikörper anti-fgfr4
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
EP3668976A1 (de) 2017-08-18 2020-06-24 Cambridge Enterprise Limited Modulare bindeproteine
JP7379323B2 (ja) 2017-08-18 2023-11-14 ザ・ジョンズ・ホプキンス・ユニバーシティ タンパク質精製のための超分子フィラメント集合体
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
TWI817952B (zh) 2017-08-25 2023-10-11 美商戊瑞治療有限公司 Ｂ７－ｈ４抗體及其使用方法
CN109422805A (zh) 2017-08-28 2019-03-05 上海易乐生物技术有限公司 多肽及结合多肽的抗体
CA3072777A1 (en) 2017-09-08 2019-03-14 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
AU2018334226A1 (en) * 2017-09-14 2020-04-02 Abbott Diagnostics Scarborough, Inc. Detection of recombinase polymerase amplification using dual-hapten probe
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
CN111164208B (zh) 2017-09-29 2023-08-04 第一三共株式会社 抗体－吡咯并苯并二氮杂卓衍生物偶联物
WO2019070013A1 (ja) 2017-10-05 2019-04-11 第一三共株式会社 細胞傷害性ｔ細胞枯渇用組成物
TW201930351A (zh) 2017-10-06 2019-08-01 日商小野藥品工業股份有限公司 雙特異性抗體
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
EP3700933A1 (de) 2017-10-25 2020-09-02 Novartis AG Gegen cd32b gerichtete antikörper und verfahren zur verwendung davon
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019089594A1 (en) 2017-10-31 2019-05-09 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
SG11202003980PA (en) 2017-10-31 2020-05-28 Staten Biotechnology B V Anti-apoc3 antibodies and methods of use thereof
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
EP3713961A2 (de) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung
JP7165193B2 (ja) 2017-11-27 2022-11-02 パーデュー、ファーマ、リミテッド、パートナーシップ ヒト組織因子を標的とするヒト化抗体
CA3083346A1 (en) 2017-11-28 2019-06-06 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand-binding activity
EP3717011B1 (de) 2017-11-29 2022-12-07 CSL Limited Verfahren zur behandlung oder prävention von ischämischen reperfusionsläsionen
AU2018378804A1 (en) 2017-12-06 2020-06-11 Ensoma, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
BR112020010085A2 (pt) 2017-12-09 2020-10-13 Abbott Laboratories métodos para auxiliar no diagnóstico e avaliar uma lesão cerebral traumática em um indivíduo humano usando uma combinação de gfap e uch-l1
AU2018378971A1 (en) 2017-12-09 2020-01-02 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1)
EP3502139A1 (de) 2017-12-19 2019-06-26 Philogen S.p.A. Antikörper gegen tumorantigene
CA3085472A1 (en) 2017-12-19 2019-06-27 The Rockefeller University Human igg fc domain variants with improved effector function
EP3732195A4 (de) 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha Zytotoxizitätsinduzierendes therapeutikum
EP3732178A1 (de) 2017-12-28 2020-11-04 ImmunoGen, Inc. Benzodiazepinderivate
MX2020006956A (es) 2018-01-05 2020-11-06 Ac Immune Sa Moleculas de union a tdp-43 mal plegadas.
EP3508499A1 (de) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antikörper zum targeting von, und andere modulatoren von, einem immunglobulingen im zusammenhang mit resistenz gegen antitumor-immunantworten und verwendungen davon
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
JP7458790B2 (ja) 2018-01-31 2024-04-01 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
US11512127B2 (en) 2018-02-14 2022-11-29 Viela Bio, Inc. Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
AU2019220395A1 (en) 2018-02-14 2020-09-10 Abba Therapeutics Ag Anti-human PD-L2 antibodies
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
MA52416A (fr) 2018-03-02 2021-04-21 Five Prime Therapeutics Inc Anticorps b7-h4 et leurs procédés d'utilisation
US11859006B2 (en) 2018-03-05 2024-01-02 Saitama Medical University Method of treating ectopic ossification or diffuse intrinsic pontine glioma in a subject by administering an anti-ALK2 antibody
US20190269757A1 (en) 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
CN112262155A (zh) 2018-03-14 2021-01-22 表面肿瘤学公司 结合cd39的抗体及其用途
EP3765497A1 (de) 2018-03-14 2021-01-20 F. Hoffmann-La Roche AG Neuartige anti-troponin-t-antikörper
KR20200131838A (ko) 2018-03-14 2020-11-24 에프. 호프만-라 로슈 아게 항체의 친화성 성숙화를 위한 방법
CN112512571A (zh) 2018-03-22 2021-03-16 表面肿瘤学公司 抗il-27抗体及其用途
CN111886256A (zh) 2018-03-23 2020-11-03 百时美施贵宝公司 抗mica和/或micb抗体及其用途
JP2021519752A (ja) 2018-03-29 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 単量体モノクローナル抗体を精製する方法
US11155618B2 (en) 2018-04-02 2021-10-26 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
JP2021521273A (ja) 2018-04-12 2021-08-26 メディアファーマ エス．アール．エル． Ｌｇａｌｓ３ｂｐ抗体−薬剤結合体及びがん治療のためのその使用
WO2019209995A2 (en) 2018-04-25 2019-10-31 Precision Ibd, Inc. Optimized anti-tl1a antibodies
EP3784274A1 (de) 2018-04-27 2021-03-03 Fondazione Ebri Rita Levi-Montalcini Gegen ein tau-abgeleitetes neurotoxisches peptid gerichteter antikörper und verwendungen davon
MX2020011468A (es) 2018-04-30 2021-02-09 Medimmune Ltd Conjugados para detectar selectivamente y eliminar agregados.
JP2021523138A (ja) 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法
WO2019222130A1 (en) 2018-05-15 2019-11-21 Immunogen, Inc. Combination treatment with antibody-drug conjugates and flt3 inhibitors
WO2019222281A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc Improved lamp constructs comprising allergens
CA3100157A1 (en) 2018-05-16 2019-11-21 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
TW202003580A (zh) 2018-05-21 2020-01-16 美商坎伯斯治療有限責任公司 用於增強nk細胞對標靶細胞之殺死之組合物及方法
EP3797752A4 (de) 2018-05-21 2022-03-02 Chugai Seiyaku Kabushiki Kaisha In einem glasfläschchen verschlossene lyophilisierte formulierung
KR20210015902A (ko) 2018-05-24 2021-02-10 얀센 바이오테크 인코포레이티드 Psma 결합제 및 이의 용도
WO2019224713A2 (en) 2018-05-24 2019-11-28 Janssen Biotech, Inc. Monospecific and multispecific anti-tmeff2 antibodies and there uses
JOP20200302A1 (ar) 2018-05-24 2020-11-23 Janssen Biotech Inc الأجسام المضادة لـ cd3 واستخداماتها
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
BR112020025661A2 (pt) 2018-06-18 2021-03-23 UCB Biopharma SRL antagonista anti-grem1, agente anticâncer, métodos de tratamento de um câncer e de prognosticar um câncer, composição ou kit, métodos para a detecção de câncer, para determinar se um paciente com ou com suspeita de ter ou com risco de desenvolver câncer é ou não susceptível de responder ao tratamento com um agente quimioterápico, e para determinar se um paciente com ou com suspeita de ter ou com risco de desenvolver câncer tem probabilidade de responder ao tratamento com um antagonista de grem1
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
KR20210040945A (ko) 2018-06-21 2021-04-14 유마니티 테라퓨틱스, 인크. 신경장애의 치료 및 예방을 위한 조성물 및 방법
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
US20200025776A1 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
EP3824287A1 (de) 2018-07-20 2021-05-26 Pierre Fabre Médicament Rezeptor für vista
EP3833442A2 (de) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antikörper zur bindung von cd277 und verwendungen davon
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020033923A1 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antigen binding agents that bind cd277 and uses thereof
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
US20220047701A1 (en) 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
SI3883606T1 (sl) 2018-09-24 2023-10-30 Janssen Biotech, Inc. Varen in učinkovit postopek zdravljenja ulceroznega kolitisa s protitelesom proti IL12/IL23
CA3114295A1 (en) 2018-09-28 2020-04-02 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
MA53811A (fr) 2018-10-03 2022-03-16 Staten Biotechnology B V Anticorps spécifiques à l'apoc3 humaine et du cynomolgus et procédés pour leur utilisation
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020081881A2 (en) 2018-10-17 2020-04-23 Janssen Biotech, Inc. Method of providing subcutaneous administration of anti-cd38 antibodies
BR112021007765A2 (pt) 2018-10-23 2021-08-03 Scholar Rock, Inc. inibidores seletivos de rgmc e uso dos mesmos
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
WO2020084056A1 (en) 2018-10-25 2020-04-30 Swiss Pharma International Ag Anti-human cd89 antibodies and uses thereof
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
AU2019375036A1 (en) 2018-11-05 2021-06-03 Centre Hospitalier Universitaire Vaudois Humanized and variant TGF-beta1 specific antibodies and methods and uses thereof
CN113613726A (zh) 2018-11-05 2021-11-05 路德维格癌症研究所有限公司 人源化和变体TGF-β3特异性抗体及其方法和用途
AU2019379576A1 (en) 2018-11-13 2021-06-03 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
SG11202104993SA (en) 2018-11-14 2021-06-29 Daiichi Sankyo Co Ltd Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
JP2022509942A (ja) 2018-11-16 2022-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗ｎｋｇ２ａ抗体およびその使用
US20220332800A1 (en) 2018-11-20 2022-10-20 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
US11548941B2 (en) 2018-11-20 2023-01-10 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
US20220332838A1 (en) 2018-11-20 2022-10-20 Perseus Proteomics Inc. Agent for inhibiting iron uptake into cells
WO2020128864A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
TW202031684A (zh) 2018-12-20 2020-09-01 日商協和麒麟股份有限公司 Fn14抗體及其用途
WO2020132396A1 (en) 2018-12-20 2020-06-25 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
EP3902824A4 (de) 2018-12-28 2023-01-04 Sparx Therapeutics Inc. Für claudin 18.2 spezifische bindungsmoleküle, zusammensetzungen und verfahren zur behandlung von krebs und anderen krankheiten
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
JP2022518208A (ja) 2019-01-15 2022-03-14 ヤンセン バイオテツク，インコーポレーテツド 若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
WO2020150496A1 (en) 2019-01-16 2020-07-23 Compass Therapeutics Llc Formulations of antibodies that bind human cd137 and uses thereof
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
WO2020154293A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
JP2022518250A (ja) 2019-01-23 2022-03-14 ヤンセン バイオテツク，インコーポレーテツド 乾癬性関節炎の治療方法で使用するための抗ｔｎｆ抗体組成物
CN113329770A (zh) 2019-01-24 2021-08-31 中外制药株式会社 新型癌抗原及所述抗原的抗体
CR20210416A (es) 2019-01-30 2021-09-14 Scholar Rock Inc INHIBIDORES ESPECIFICOS DEL COMPLEJO DE LTBP DE TGFß Y USOS DE LOS MISMOS
EP3917968A1 (de) 2019-01-30 2021-12-08 Nomocan Pharmaceuticals LLC Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
WO2020169840A1 (en) 2019-02-21 2020-08-27 Cambridge Enterprise Limited Bispecific proteins with a chimeric scaffold
GB201902392D0 (en) 2019-02-21 2019-04-10 Cambridge Entpr Ltd Modular binding proteins
FI3930847T3 (fi) 2019-02-26 2024-04-23 Inspirna Inc Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä
CN113508140A (zh) 2019-02-28 2021-10-15 学校法人顺天堂 与切断型的突变型Calreticulin结合的抗体以及骨髄增殖性肿瘤的诊断、预防或治疗药
JP2022525145A (ja) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体組成物を生成するための製造方法
MA55284A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
MA55283A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
JP2022525179A (ja) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための産生方法
JP2022526493A (ja) 2019-03-18 2022-05-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体を用いた小児被験者の乾癬の治療方法
EP3943108A4 (de) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Antigen-bindendes molekül mit antigen-bindender domäne mit veränderlicher bindungsaktivität gegenüber antigen in abhängigkeit von mta und bibliothek zur gewinnung der antigen-bindenden domäne
US20220177558A1 (en) 2019-03-25 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
KR20210141630A (ko) 2019-03-25 2021-11-23 다이이찌 산쿄 가부시키가이샤 항 her2 항체-피롤로벤조디아제핀 유도체 콘주게이트
TW202102228A (zh) 2019-03-25 2021-01-16 日商第一三共股份有限公司 抗體-吡咯并苯二氮呯衍生物結合物
WO2020196712A1 (ja) 2019-03-27 2020-10-01 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲートとｐａｒｐ阻害剤の組み合わせ
JP2022527506A (ja) 2019-03-27 2022-06-02 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Ｃｄ４０活性化特性を有する組換えタンパク質
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
US20220042954A1 (en) 2019-03-29 2022-02-10 Bristol-Myers Squibb Company Methods of measuring hydrophobicity of chromatographic resins
TW202102544A (zh) 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
CN113906042A (zh) 2019-04-10 2022-01-07 中外制药株式会社 用于纯化fc区修饰抗体的方法
JP2022529943A (ja) 2019-04-15 2022-06-27 クウィクセル セラピューティクス リミテッド ライアビリティ カンパニー がんの処置における使用のための、標的指向性のマスクされたｉ型インターフェロン（ｉｆｎａおよびｉｆｎｂ）と腫瘍抗原に対する抗体とを含む融合タンパク質組成物
TW202110477A (zh) 2019-04-17 2021-03-16 國立大學法人廣島大學 以組合投予il-6 抑制劑與ccr2 抑制劑為特徵之泌尿器官癌的治療劑
CA3136888A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
JP2022530026A (ja) 2019-04-24 2022-06-27 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング アマトキシン抗体薬物複合体及びその使用
CN114127312A (zh) 2019-04-30 2022-03-01 拉利玛生物医药公司 用于测定共济蛋白替代疗法的疗效的共济蛋白敏感性标志物
TW202110879A (zh) 2019-05-23 2021-03-16 瑞士商Ａｃ 免疫有限公司 抗tdp-43結合分子及其用途
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
KR20220015445A (ko) 2019-05-29 2022-02-08 다이이찌 산쿄 가부시키가이샤 항체-약물 접합체의 투약
BR112021024425A2 (pt) 2019-06-03 2022-01-18 Janssen Biotech Inc Composições de anticorpo anti-tnf e métodos para o tratamento de artrite psoriática
BR112021024401A2 (pt) 2019-06-03 2022-04-19 Janssen Biotech Inc Anticorpos anti-tnf, composições e métodos para o tratamento de espondilite anquilosante ativa
JPWO2020246563A1 (de) 2019-06-05 2020-12-10
CN113966345A (zh) 2019-06-12 2022-01-21 诺华股份有限公司 利钠肽受体1抗体及使用方法
JP6881658B2 (ja) 2019-07-05 2021-06-02 小野薬品工業株式会社 Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
EP3994171A1 (de) 2019-07-05 2022-05-11 iOmx Therapeutics AG Igc2 von igsf11 (vsig3) bindende antikörper und ihre verwendungen
EP4004044A1 (de) 2019-07-24 2022-06-01 H. Lundbeck A/S Anti-mglur5-antikörper und verwendungen davon
EP4008350A4 (de) 2019-07-26 2023-06-14 Saitama Medical University Antikörper, der die extrazelluläre region von alk2/acvr1 erkennt
BR112022001473A2 (pt) 2019-07-30 2022-03-22 Ono Pharmaceutical Co Anticorpo biespecífico
EP4011918A4 (de) 2019-08-08 2023-08-23 ONO Pharmaceutical Co., Ltd. Dual-spezifisches protein
JP2022545368A (ja) 2019-08-12 2022-10-27 アプティーボ リサーチ アンド デベロップメント エルエルシー ４－１ｂｂおよび０ｘ４０結合タンパク質ならびに関連する組成物および方法、４－１ｂｂに対する抗体、０ｘ４０に対する抗体
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
PE20221151A1 (es) 2019-08-30 2022-07-18 Agenus Inc Anticuerpos anti-cd96 y sus metodos de uso
JP2022546768A (ja) 2019-09-04 2022-11-08 ワイ－バイオロジクス・インコーポレイテッド 抗ｖｓｉｇ４抗体または抗原結合フラグメントおよびその使用
CN114364699B (zh) 2019-09-04 2024-03-29 株式会社英仙蛋白质科学 红细胞增多症治疗药
WO2021046261A1 (en) 2019-09-05 2021-03-11 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
MX2022003005A (es) 2019-09-16 2022-04-07 Surface Oncology Inc Composiciones y metodos de anticuerpos anti-cd39.
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
AU2020353672A1 (en) 2019-09-25 2022-03-31 Surface Oncology, LLC Anti-IL-27 antibodies and uses thereof
US20220411511A1 (en) 2019-09-26 2022-12-29 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
CN114450304B (zh) 2019-09-27 2023-12-12 国家医疗保健研究所 抗苗勒管抑制物质抗体及其用途
AU2020357550A1 (en) 2019-10-04 2022-05-05 Tae Life Sciences, Llc Antibody compositions comprising Fc mutations and site-specific conjugation properties
JP2022552282A (ja) 2019-10-09 2022-12-15 エスティーキューブ アンド カンパニー グリコシル化ｌａｇ３に対して特異的な抗体およびその使用方法
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
EP4045061A4 (de) 2019-10-14 2024-04-17 Aro Biotherapeutics Company Cd71-bindende fibronectin-typ iii-domänen
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
CA3155172A1 (en) 2019-10-25 2021-04-29 Shinko HAYASHI Combination of anti-garp antibody and immunomodulator
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
JP2023500506A (ja) 2019-11-04 2023-01-06 アストラゼネカ・アクチエボラーグ 癌を治療するための組み合わせ療法
EP3822288A1 (de) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Gegen das cd276-antigen gerichtete antikörper, und andere modulatoren gegen das cd276-antigen, und deren verwendung
CA3161800A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
KR20220131895A (ko) 2019-11-21 2022-09-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법
JPWO2021107082A1 (de) 2019-11-27 2021-06-03
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
US20230040928A1 (en) 2019-12-09 2023-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
US20210188971A1 (en) 2019-12-19 2021-06-24 Quidel Corporation Monoclonal antibody fusions
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
EP4077395A1 (de) 2019-12-20 2022-10-26 Poseida Therapeutics, Inc. Anti-muc1-zusammensetzungen und verfahren zur verwendung
CN115087672A (zh) 2019-12-24 2022-09-20 Jjp佰优罗机克斯有限公司 抗人hvem(tnfrsf14)抗体及其用途
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
EP4087607A1 (de) 2020-01-06 2022-11-16 Vaccinex, Inc. Anti-ccr8-antikörper und verwendungen davon
CN115052663A (zh) 2020-01-08 2022-09-13 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
CN115697388A (zh) 2020-01-30 2023-02-03 优莫佳生物制药股份有限公司 双特异性转导增强子
EP4100435A1 (de) 2020-02-05 2022-12-14 Larimar Therapeutics, Inc. Tat-peptidbindende proteine und ihre verwendungen
EP4103608A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispezifische antikörper gegen cd9 und cd137
EP4103609A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispezifische antikörper gegen cd9 und cd7
US20230192900A1 (en) 2020-02-13 2023-06-22 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
WO2021160268A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9
CN113248611A (zh) 2020-02-13 2021-08-13 湖南华康恒健生物技术有限公司 抗bcma抗体、其药物组合物及应用
WO2021160269A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
EP4106788A1 (de) 2020-02-18 2022-12-28 Alector LLC Pilra-antikörper und verfahren zur verwendung davon
CA3174103A1 (en) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
US20230235073A1 (en) 2020-03-06 2023-07-27 Ona Therapeutics, S.L. Anti-cd36 antibodies and their use to treat cancer
JP2023517889A (ja) 2020-03-10 2023-04-27 マサチューセッツ インスティテュート オブ テクノロジー ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
EP4118107A1 (de) 2020-03-11 2023-01-18 Poseida Therapeutics, Inc. Chimäre stimulationsrezeptoren und verfahren zur verwendung bei der t-zell-aktivierung und -differenzierung
US20230135752A1 (en) 2020-03-27 2023-05-04 PhotoQ3 Inc. Medicament for killing tumor cells
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
JP7285495B2 (ja) 2020-03-30 2023-06-02 国立大学法人三重大学 二重特異的抗体
CN115379858A (zh) 2020-04-06 2022-11-22 光爱科技公司 用于杀死肿瘤细胞的医药品
CA3173861A1 (en) 2020-04-10 2021-10-14 Rudolf Ubelhart Natural antibodies in prophylaxis and therapy
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
CA3174777A1 (en) 2020-04-14 2021-10-21 Eric M. Ostertag Compositions and methods for use in the treatment of cancer
WO2021215919A1 (en) 2020-04-21 2021-10-28 Polpharma Biologics Utrecht B.V. Humanized anti-human cd89 antibodies and uses thereof
CA3176979A1 (en) 2020-04-27 2021-11-04 Anthony Boitano Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
EP4143236A1 (de) 2020-05-01 2023-03-08 Novartis AG Manipulierte immunglobuline
JP2023523760A (ja) 2020-05-01 2023-06-07 ノバルティス アーゲー 免疫グロブリン変異体
JP2023525053A (ja) 2020-05-12 2023-06-14 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 皮膚ｔ細胞リンパ腫及びｔｆｈ由来リンパ腫を処置する新しい方法
US20230183366A1 (en) 2020-05-13 2023-06-15 Inserm (Institut National De La Santé Et De La Recherch Médicale) Recombinant proteins with ox40 activating properties
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
WO2021233834A1 (en) 2020-05-17 2021-11-25 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of selecting and using the same
JPWO2021261546A1 (de) 2020-06-24 2021-12-30
EP4175668A1 (de) 2020-07-06 2023-05-10 iOmx Therapeutics AG Igv von igsf11 (vsig3) bindende antikörper und verwendungen davon
BR112023000482A2 (pt) 2020-07-16 2023-01-31 Novartis Ag Anticorpos antibetacelulina, fragmentos dos mesmos e moléculas de ligação multiespecíficas
US20230279078A1 (en) 2020-07-20 2023-09-07 Astrazeneca Uk Limited Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the same
AU2021315210A1 (en) 2020-07-28 2023-03-09 Chugai Seiyaku Kabushiki Kaisha Prefilled syringe formulation with needle with needle shield containing novel modified antibody
TW202220677A (zh) 2020-07-31 2022-06-01 日商中外製藥股份有限公司 含有表現嵌合受體之細胞的醫藥組成物
EP4190813A1 (de) 2020-07-31 2023-06-07 Bio-Thera Solutions, Ltd. Cd47-antikörper und anwendung davon
CA3188349A1 (en) 2020-08-04 2022-02-10 A. Scott Muerhoff Improved methods and kits for detecting sars-cov-2 protein in a sample
KR20230066149A (ko) 2020-08-07 2023-05-12 포티스 테라퓨틱스, 인크. Cd46을 표적화하는 면역접합체 및 이의 사용 방법
EP4196162A1 (de) 2020-08-14 2023-06-21 AC Immune SA Humanisierte anti-tdp-43-bindungsmoleküle und verwendungen davon
WO2022040345A1 (en) 2020-08-18 2022-02-24 Cephalon, Inc. Anti-par-2 antibodies and methods of use thereof
CN114106173A (zh) 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
EP4204448A2 (de) 2020-08-27 2023-07-05 cureab GmbH Anti-golph2-antikörper zur makrophagen- und dendritischen zelldifferenzierung
IL300764A (en) 2020-08-27 2023-04-01 Juntendo Educational Found Antibody and composition of calr-cd3 mutant anti-clotting drugs
WO2022047359A1 (en) 2020-08-31 2022-03-03 Berg Llc Protein biomarkers for pancreatic cancer
EP4208197A1 (de) 2020-09-04 2023-07-12 Rutgers, The State University of New Jersey Sars-cov-2-impfstoffe und -antikörper
AU2021339953A1 (en) 2020-09-11 2023-05-18 Medimmune Limited Therapeutic b7-h4 binding molecules
CN116615455A (zh) 2020-09-12 2023-08-18 免疫医疗有限公司 用于抗b7h4抗体-药物缀合物疗法的评分方法
WO2022075439A1 (ja) 2020-10-08 2022-04-14 国立大学法人東海国立大学機構 抗トランスフェリンレセプター抗体の薬効又は感受性の判定方法
IL301859A (en) 2020-10-15 2023-06-01 UCB Biopharma SRL Binding molecules for CD45 multimerization
EP4229081A1 (de) 2020-10-15 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Für sars-cov-2-rezeptor-bindungsdomäne spezifischer antikörper und therapeutische verfahren
EP4232475A1 (de) 2020-10-20 2023-08-30 Kantonsspital St. Gallen Antikörper oder antigenbindende fragmente mit spezifischer bindung an gremlin-1 und verwendungen davon
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
EP3992205A1 (de) 2020-11-03 2022-05-04 Rheinische Friedrich-Wilhelms-Universität Bonn Verbindung zum binden des sars coronavirus-2 spike-proteins
CA3173151A1 (en) 2020-11-03 2022-05-12 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
JP2023547499A (ja) 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
CN114478770A (zh) 2020-11-12 2022-05-13 迈威(上海)生物科技股份有限公司 抗体及其制备方法
WO2022106205A1 (en) 2020-11-18 2022-05-27 Rheinische Friedrich-Wilhelms-Universität Bonn Corona virus spike protein binding compounds
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4259661A1 (de) 2020-12-14 2023-10-18 Novartis AG Reverse bindemittel für anti-natriuretische peptidrezeptor-1 (npr1)-antikörper und verwendungen davon
EP4271998A1 (de) 2020-12-30 2023-11-08 Abbott Laboratories Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
CN117425501A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
US20240115721A1 (en) 2021-01-13 2024-04-11 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
US20240059789A1 (en) 2021-01-28 2024-02-22 Janssen Biotech, Inc. Psma binding proteins and uses thereof
WO2022162201A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
WO2022162203A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
CN117120084A (zh) 2021-01-28 2023-11-24 维肯芬特有限责任公司 用于调节b细胞介导的免疫应答的方法和手段
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
US20220378929A1 (en) 2021-02-25 2022-12-01 MediBoston Limted Anti-her2 antibody-drug conjugates and uses thereof
TW202302645A (zh) 2021-03-03 2023-01-16 法商皮爾法伯製藥公司 抗vsig4抗體或抗原結合片段及其用途
JP2024512324A (ja) 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
BR112023018400A2 (pt) 2021-03-12 2023-12-12 Janssen Biotech Inc Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23
TW202302143A (zh) 2021-03-12 2023-01-16 日商中外製藥股份有限公司 重症肌無力症之治療或預防用之醫藥組合物
IL305802A (en) 2021-03-12 2023-11-01 Janssen Biotech Inc A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
EP4308607A2 (de) 2021-03-18 2024-01-24 MedImmune Limited An ccr9 bindendes therapeutisches bindungsmolekül
TW202304991A (zh) 2021-03-29 2023-02-01 日商第一三共股份有限公司 穩定的多重特異性分子及其利用
EP4067381A1 (de) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Neue tnfr2-bindende moleküle
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
IL307530A (en) 2021-04-06 2023-12-01 Bpgbio Inc Estrogen receptor-like (ER) breast cancer protein markers LUMINAL A (LA) and LUMINAL B1 (LB1)
EP4320443A1 (de) 2021-04-06 2024-02-14 BPGbio, Inc. Proteinmarker zur prognose der brustkrebsprogression
IL307531A (en) 2021-04-06 2023-12-01 Bpgbio Inc Protein markers for estrogen receptor (ER)-like and estrogen receptor (ER)-negative breast cancer
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
CN113156121B (zh) * 2021-04-16 2021-12-07 苏州东尼生物技术有限公司 一种用于检测人甲状腺球蛋白的胶体金试纸条
BR112023022878A2 (pt) 2021-05-04 2024-01-23 Regeneron Pharma Agonistas do receptor fgf21 multiespecíficos e seus usos
WO2022236134A1 (en) 2021-05-07 2022-11-10 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
CA3216320A1 (en) 2021-05-18 2022-11-24 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
EP4348263A1 (de) 2021-05-28 2024-04-10 Alexion Pharmaceuticals, Inc. Verfahren zum nachweis von cm-tma-biomarkern
WO2022263357A1 (en) 2021-06-14 2022-12-22 Argenx Iip Bv Anti-il-9 antibodies and methods of use thereof
WO2022266034A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
CN117529330A (zh) 2021-06-18 2024-02-06 纳米医疗有限公司 用于治疗癌症的包括所掩蔽的I型干扰素(IFNα和IFNβ)的融合蛋白组合物和其方法
CA3221555A1 (en) 2021-06-23 2022-12-29 Kimberly LONG A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
IL309405A (en) 2021-06-29 2024-02-01 Seagen Inc Methods for treating cancer with a combination of non-fucosylated anti-CD70 antibody and CD47 antagonist
KR20240034218A (ko) 2021-07-09 2024-03-13 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생산하기 위한 제조 방법
KR20240032991A (ko) 2021-07-09 2024-03-12 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 생성을 위한 제조 방법
IL309987A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-IL12/IL23 antibody compositions
WO2023285878A1 (en) 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
WO2023286854A1 (ja) 2021-07-16 2023-01-19 ブライトパス・バイオ株式会社 抗Ｔｉｍ－３抗原抗体または抗体誘導体およびその用途
WO2023007472A1 (en) 2021-07-30 2023-02-02 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
CA3228178A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
WO2023027164A1 (ja) 2021-08-26 2023-03-02 株式会社ペルセウスプロテオミクス Ｒｏｓ（活性酸素種）産生増強剤
TW202323289A (zh) 2021-08-31 2023-06-16 日商大正製藥股份有限公司 抗生長激素抗體
AU2022339759A1 (en) 2021-08-31 2024-03-07 Abbott Laboratories Methods and systems of diagnosing brain injury
TW202325733A (zh) 2021-09-03 2023-07-01 美商Ｇｏ治療公司 抗醣化-lamp1抗體及其用途
TW202328188A (zh) 2021-09-03 2023-07-16 美商Ｇｏ治療公司 抗醣化-cmet抗體及其用途
WO2023042097A1 (en) 2021-09-15 2023-03-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
WO2023056268A1 (en) 2021-09-30 2023-04-06 Abbott Laboratories Methods and systems of diagnosing brain injury
WO2023057871A1 (en) 2021-10-04 2023-04-13 Novartis Ag Surfactant stabilizers
CA3233506A1 (en) 2021-10-04 2023-04-13 Joseph S. LUCAS Transposon compositions and methods of use thereof
TW202323810A (zh) 2021-10-08 2023-06-16 日商中外製藥股份有限公司 預填充式注射器製劑的調製方法
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230136301A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
EP4177266A1 (de) 2021-11-05 2023-05-10 Katholieke Universiteit Leuven Neutralisierende humane anti-sars-cov-2-antikörper
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
AR127692A1 (es) 2021-11-16 2024-02-21 Ac Immune Sa Anticuerpos anti-asc para uso en tratamientos antiinflamatorios
WO2023090361A1 (ja) 2021-11-16 2023-05-25 国立大学法人鳥取大学 改変ｄ領域を含むヒト免疫グロブリン重鎖遺伝子座を有する哺乳動物人工染色体ベクター、及びそのベクターを保持する細胞又は非ヒト動物
WO2023095000A1 (en) 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
US20230213536A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023141576A1 (en) 2022-01-21 2023-07-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
US20230295348A1 (en) 2022-01-24 2023-09-21 Novimmune Sa Composition and methods for the selective activation of cytokine signaling pathways
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
TW202342519A (zh) 2022-02-16 2023-11-01 瑞士商Ａｃ 免疫有限公司 人源化抗ｔｄｐ－４３結合分子及其用途
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
WO2023166081A1 (en) 2022-03-02 2023-09-07 Heidelberg Immunotherapeutics Gmbh Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
WO2023170474A1 (en) 2022-03-07 2023-09-14 Novimmune Sa Cd28 bispecific antibodies for targeted t cell activation
WO2023169896A1 (en) 2022-03-09 2023-09-14 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
WO2023170216A1 (en) 2022-03-11 2023-09-14 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
WO2023175171A1 (en) 2022-03-18 2023-09-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Bk polyomavirus antibodies and uses thereof
WO2023192436A1 (en) 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples
WO2023196937A1 (en) 2022-04-06 2023-10-12 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring frataxin replacement therapy
WO2023194539A1 (en) 2022-04-07 2023-10-12 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index of amatoxin-antibody conjugates
WO2023194565A1 (en) 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
WO2023203177A1 (en) 2022-04-20 2023-10-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
WO2023228095A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240201A1 (en) 2022-06-08 2023-12-14 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024006961A1 (en) 2022-07-01 2024-01-04 Neoleukin Therapeutics, Inc. Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024050354A1 (en) 2022-08-31 2024-03-07 Washington University Alphavirus antigen binding antibodies and uses thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024054436A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1988006630A1 (en) * 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
ATE120761T1 (de) * 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE3744595A1 (de) 1987-12-31 1989-07-13 Andreas Dr Plueckthun Verfahren zur gentechnischen herstellung von antikoerpern
EP1026240A3 (de) * 1988-09-02 2004-04-07 Dyax Corp. Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5688666A (en) * 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
ES2052027T5 (es) * 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU652539B2 (en) * 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016842A1 (en) * 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) * 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2064915C (en) 1989-08-07 2001-05-29 Deborah A. Rathjen Tumour necrosis factor binding ligands
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) * 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
DE4002897A1 (de) 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
JP3043407B2 (ja) 1990-02-15 2000-05-22 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル 完全合成アフィニティ試薬
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US7063943B1 (en) * 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US6172197B1 (en) * 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
ATE185601T1 (de) * 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
US5258289A (en) 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
IL99552A0 (en) * 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US6893845B1 (en) * 1990-09-28 2005-05-17 Applied Molecular Evolution, Inc. Surface expression libraries of heteromeric receptors
IE65042B1 (en) 1990-11-08 1995-10-04 Buchlane Investments Ltd A work piece stabilising device
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
ES2113940T3 (es) * 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
ATE177782T1 (de) 1990-12-20 1999-04-15 Ixsys Inc Optimierung von bindenden proteinen
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
EP0580737B1 (de) * 1991-04-10 2004-06-16 The Scripps Research Institute Bibliotheken heterodimerer rezeptoren mittels phagemiden
US5858657A (en) * 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) * 1991-05-15 2000-03-09 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
US6225447B1 (en) * 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ATE175997T1 (de) 1991-08-10 1999-02-15 Medical Res Council Behandlung von zellpopulationen
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
AU665221B2 (en) 1991-12-02 1995-12-21 Cambridge Antibody Technology Limited Production of anti-self antibodies from antibody segment repertoires and displayed on phage
ES2168277T3 (es) * 1992-09-04 2002-06-16 Scripps Research Inst Fagemidos que coexpresan un receptor de superficie y una proteina heterologa de superficie.
CA2150262C (en) * 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US5916605A (en) * 1996-09-27 1999-06-29 Dynisco Hotrunners, Inc. Valve actuated injection molding apparatus
US5935523A (en) * 1997-05-29 1999-08-10 Medical Laboratory Automation, Inc. Apparatus for accessing a sealed container
CA2527694C (en) * 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs

Also Published As

Publication number Publication date
US6582915B1 (en) 2003-06-24
US20030190674A1 (en) 2003-10-09
ES2227512T3 (es) 2005-04-01
ES2313867T3 (es) 2009-03-16
US20090325815A1 (en) 2009-12-31
US6593081B1 (en) 2003-07-15
US7195866B2 (en) 2007-03-27
ES2341666T3 (es) 2010-06-24
US6555313B1 (en) 2003-04-29
PT1696031E (pt) 2010-06-25
US5885793A (en) 1999-03-23
ATE463573T1 (de) 2010-04-15
US20070232790A1 (en) 2007-10-04
WO1993011236A1 (en) 1993-06-10
DE69233782D1 (de) 2010-05-20
US20080050359A1 (en) 2008-02-28
DE69233745D1 (de) 2008-10-23
US6544731B1 (en) 2003-04-08
US6521404B1 (en) 2003-02-18
PT1024191E (pt) 2008-12-22
ATE408012T1 (de) 2008-09-15
DK1024191T3 (da) 2008-12-08

Similar Documents

Publication Publication Date Title
ATE275198T1 (de) Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
CA2124460A1 (en) Production of anti-self antibodies from segment repertoires and displayed on phage
DE69233791D1 (de) Verfahren zur Manipulation der Zelldifferenzierung
DK1054018T3 (da) Fab-fragmentbiblioteker og fremgangsmåde til anvendelse deraf
DK0626390T3 (da) Humaniserede antistoffer
WO2003050531A3 (en) Method for displaying loops from immunoglobulin domains in different contexts
CA2119930A1 (en) Production of chimeric antibodies - a combinatorial approach
TW200516083A (en) Methods for making dual specificity antibodies
DE69619493D1 (de) Polypeptid-dendrimer komplexe
DE50114639D1 (de) Verfahren zur antigen-spezifischen stimulation von t-lymphozyten mit synthetischen peptidbibliotheken
DE69029808D1 (de) Monoklonale antikörper
Ong et al. Re-evaluation of the concept of functional affinity as applied to bivalent antibody binding to cell surface antigens
KR890702031A (ko) 사람의 감마, 델타 t세포 항원수용체 폴리펩티드 및 헥산
EP0331514A3 (de) Prüfung der Deletion oder des Mangels an Protein von Duchenne-Muskeldystrophie
Van Erp et al. Affinity of monoclonal antibodies Interpretation of the positive cooperative nature of anti-hCG/hCG interactions
DK329789D0 (da) Monoklonalt antistof
Paus et al. TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins
Davis et al. Monoclonal antibodies in simultaneous marking ELISA systems
UY23620A1 (es) Polipeptidos sinteticos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0616640

Country of ref document: EP